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Historical perspective
It is thought that Bonet in 1679 and Wiseman in 1696 were the first to identify that 
intracranial aneurysms are causative of subarachnoid hemorrhage (SAH).3 The earliest 
verified case-report of a ruptured intracranial aneurysm (basilar artery) is probably that 
of Blackall in 1814.1,2 Initial reports on the surgical management of ruptured aneurysms 
concerned craniotomies that were conducted to treat suspected brain tumors, with 
intracranial aneurysms subsequently being discovered during this surgery.8 In 1885, Victor 
Horsely was the first to carry out a ligation of both carotid arteries for the treatment of an 
intracranial aneurysm.13 Norman Dott then performed a successful wrapping of an aneurysm 
in 1931.7 A major step forward in aneurysm treatment was achieved by Walter Dandy in 
1937, who was the first to use a metal clip to obliterate an aneurysm.4 Simultaneously, 
the advent of the cerebral angiography as a result of the work by Egas Moniz in the early 
1930s made the imaging of the aneurysms possible.17 The introduction of the operation 
microscope by Yasargil and the use of associated micro-instrumentation in the 1960s led 
to a dramatic improvement in results.14 Further advancements were made in using the 
calcium antagonist nimodipine and maintaining a high fluid intake to reduce the risk of 
delayed cerebral ischaemia.21 Surgical clipping remained the only treatment option for 
treating aneurysms for decades. However, the development of the Guglielmi detachable 
coil (GDC) in 1990 made endovascular treatment possible.9,10 Increased experience of this 
technique finally led to the International Subarachnoid Aneurysm Trial (ISAT), where 
open surgical clipping was compared to endovascular coiling for the treatment of ruptured 
aneurysms.16 The outcome of this trial, which was interrupted following an intermediate 
analysis, revealed that endovascular coiling produced significantly better results in terms of 
survival free of disability at 1 year.16 Despite the possible, slightly increased, long-term risks 
of aneurysmal regrowth and re-bleeding that are associated with endovascular treatment, 
a shift occurred towards coiling as the preferential treatment modality. Surgical clipping 
does, however, remain the treatment of first choice for a small subset of aneurysms, for 
example, those that are broad-based or when simultaneous hematoma evacuation must 
be performed. New developments of catheters and devices like stents, intrasaccular flow 
disruptors, and flowdiverters will probably further increase the number of patients treated 
endovascularly. 
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epidemiology
The incidence of aneurysmal subarachnoid hemorrhage (aSAH) is about 9 per 100,000 
per year, and is a major cause of death and disability.15,18 The mean age at presentation is 
between 50 and 60 years.27 The incidence rate of rebleeding after an SAH has been estimated 
to be about 15% during the first 24 hours, and has a high associated mortality rate of up to 
50%.19 Closure of the aneurysm after initial SAH is the primary goal to prevent aneurysmal 
rebleeding. Common associated problems like intra cerebral hematoma or hydrocephalus 
require emergency neurosurgical treatment. Although the case fatality rate has declined over 
the years, it still remains substantial at about 30 to 40%.18 Outcomes are mainly determined 
by the clinical grade at admission, and are further influenced by age and the extent of 
the bleeding.12 Additionally, treatment complications and secondary complications like 
hydrocephalus and delayed cerebral ischemia further determine the course of the disease.20 
Rehabilitation is an essential part of treatment after the initial hospital stay. Recovery after an 
SAH can be a long-term process, and may take up to several years.26 Independence in terms 
of daily life activities is achieved in 36–51% of the patients. Cognitive dysfunction is a major 
cause of difficulties in returning to work, mood disturbances, and a reduced quality of life.23 
Quality of care 
Pioneering work with respect to quality evaluation in healthcare has been conducted by 
Avedis Donabedian, who described quality design in relation to the three-part classification 
of a structure, process, and outcome model. Structure refers to the conditions under which 
care is provided, and it includes material and human resources as well as organizational 
characteristics.5,6 The activities that constitute healthcare are assessed by process measures i.e. 
the actual process of healthcare, including diagnosis, treatment, rehabilitation, prevention, 
and patient education by professionals. Additionally, patients themselves, as well as their 
families, are also considered to be contributors to healthcare delivery. Outcome, meanwhile, 
measures the results of healthcare, which are also related to factors of a disease itself.  
More recently, the theme of quality has been redefined by Porter.22 Central in his view of 
quality is the concept of value which is characterized as the health outcomes achieved per 
dollar spent. This is defined around patients and unites all the interests of the actors in the 
system. Improving performance and accountability depends on having this shared goal. 
The result of care is not represented in a single outcome, although multiple, sometimes 
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competing, outcomes do define success. In order to determine relevant outcomes, they can 
generally be divided into three 2-level tiers: The first tier contains the health status achieved 
or retained (survival is the most important level and the degree of recovery the second level). 
The second tier incorporates the time to recovery, the time to return to normal activities at 
level one, and the disutility of care-like complications on another level. The third tier is the 
sustainability of health, and is divided into a level of sustainability of health or recovery and 
the nature of recurrences, and another level of the long-term consequences of therapy. The 
precise definition of these outcomes is disease specific. An SAH specific outcome in tiers 
is provided in Table 1.1. The measurement of outcomes should be performed with at least 
one outcome dimension in each tier. These outcomes, weighted with the costs associated 
with an entire care cycle, define value.
Quality measurement will contribute to quality improvement. Improvements in healthcare 
are generally seen as a continuous process. Several strategies or combinations thereof are in 
use, such as plan-do-study-act, six-sigma, and lean.25 Key in these improvement strategies 
is the cycle of measurement and the feedback of changes implemented to the system.
Table 1.1 Outcome Tier in aSAH
General description Aneurysmal SAH
Tier 1
Health status
achieved
or retained
Survival Mortality rate
Degree of health or recovery mRS, GOS
Tier 2
Process
of recovery
Time to recovery and time to return to normal activities (Time to) return to work
Disutility of care or treatment process
(e.g. diagnostic errors, ineffective care,
treatment-related discomfort, complications, adverse 
effects)
Rebleed
Complications
Tier 3
Sustainability
of health
Sustainability of health or recovery
and nature of recurrences
Residual aneurysm
Rebleed after treatment
Re-treatment
Long-term consequences of therapy
(e.g. care-induced illnesses)
Coping problems due 
to insufficient aftercare
The outcome measures hierarchy after Porter adopted for aneurysmal subarachnoid hemorrhage.22 mRS: 
Modified Rankin Scale, GOS: Glasgow Outcome Scale.
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subaracHnoid HemorrHage and Quality of care
This thesis evaluates several aspects of the quality of care for patients with an aSAH. Structure 
measures have been used as a set of minimum standards for healthcare. Often, minimum 
volume standards are used for complex diseases and, as indicators of quality.11,24 In the second 
chapter of this thesis, the relationship between hospital volume and outcomes for aSAH in 
the published literature is investigated. 
Outcomes in the treatment of subarachnoid hemorrhage are strongly related to the clinical 
condition at presentation. In comparing outcomes, case-mix correction is essential. However, 
it is questionable whether co-morbid conditions have a significant impact on outcomes and 
should be accounted for. The Charlson co-morbidity index is a tool used to weight co-morbid 
conditions in predicting mortality. In the third chapter, the association between outcomes 
and this index is evaluated.
Preventing a rebleed is paramount in the treatment of patients with a ruptured aneurysm, 
since this symptom is associated with high morbidity and mortality. Currently, ultra-early 
(within 24 hours) treatment is advised for patients in a good clinical condition. Non-
modifiable factors like a delayed diagnosis or a transfer from another hospital might delay 
treatment. On the other hand, suboptimal hospital logistics can be causative. In Chapter 4 
aneurysm size as a risk factor for aneurysmal rebleeding is investigated in the literature to 
identify the patients who might benefit from ultra-early treatment. 
In Chapter 5, procedure-related complications are investigated. Procedural complications can 
have devastating consequences for outcomes. The special focus of the evaluation concerns 
whether dual trained (open and endovascular) neurosurgeons have comparable results to 
open vascular neurosurgeons and interventional neuroradiologists. Having insight into the 
treatment-related complications of one’s own results, and not just of those published in the 
literature, provides a starting point for the improvement cycle.   
Care delivery should both be centered on the patient and investigate patients’ needs. In 
Chapter 6, an online health community for patients with aSAH is described and evaluated 
from a patient’s perspective. 
The follow-up of patients treated with endovascular coiling after aneurysm rupture is required 
because recurrences occur in approximately 20% of those treated, leading to a need for 
retreatment in about 9% of cases. Digital substraction angiography (DSA) is considered to be 
the reference standard for evaluating aneurysms after coiling, although it has associated risks 
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like cerebral thromboembolism and contrast nephrotoxicity, and utilizes ionizing radiation. 
Magnetic Resonance Angiography (MRA) is also used, and is more commonly available, and 
eliminates the previously-mentioned risks. However, it remains questionable whether MRA 
techniques, especially in terms of time of flight or contrast-enhanced MRA, can be used for 
follow up imaging. In Chapter 7, the accuracy of TOF-MRA and CE-MRA is evaluated in 
terms of detecting residual flow in the follow-up of coiled intracranial aneurysms.
A quality registry has been developed (Quality Registry NeuroSurgery: QRNS) to compare 
outcomes with respect to the most important parameters between centers in the Netherlands. 
The development and structure of this registry are outlined in Chapter 8.
The different parts of this thesis are then discussed in Chapter 10, while recommendations 
are made for further improvements in the quality of care registration for patients with aSAH. 
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AbstrAct
Object Increasing evidence exists that treatment of complex medical conditions in high-
volume centers is found to improve outcome. Patients with subarachnoid hemorrhage 
(SAH), a complex disease, probably also benefit from treatment at a high-volume center. 
The authors aimed to determine, based on published literature, whether a higher hospital 
caseload is associated with improved outcomes of patients undergoing treatment after 
aneurysmal subarachnoid hemorrhage.
Methods The authors identified studies from MEDLINE, Embase, and the Cochrane 
Library up to September 28, 2012, that evaluated outcome in high-volume versus low-volume 
centers in patients with SAH who were treated by either clipping or endovascular coiling. No 
language restrictions were set. The compared outcome measure was in-hospital mortality. 
Mortality in studies was pooled in a random effects meta-analysis. Study quality was reported 
according to the GRADE (Grading of Recommendations Assessment, Development and 
Evaluation) criteria.
Results Four articles were included in this analysis, representing 36,600 patients. The quality 
of studies was graded low in 3 and very low in 1. Meta-analysis using a random effects model 
showed a decrease in hospital mortality (OR 0.77 [95% CI 0.60–0.97]; p = 0.00; I2 = 91%) 
in high-volume hospitals treating SAH patients. Sensitivity analysis revealed the relative 
weight of the 1 low-quality study. Removal of the study with very low quality increased the 
effect size of the meta-analysis to an OR of 0.68 (95% CI 0.56–0.84; p = 0.00; I2 = 86%). 
The definition of hospital volume differed among studies. Cutoffs and dichotomizations 
were used as well as division in quartiles. In 1 study, low volume was defined as 9 or fewer 
patients yearly, whereas in another it was defined as fewer than 30 patients yearly. Similarly, 
1 study defined high volume as more than 20 patients annually, and another defined it as 
more than 50 patients a year. For comparability between studies, recalculation was done with 
dichotomized data if available. Cross et al., 2003 (low volume ≤ 18, high volume ≥ 19) and 
Johnston, 2000 (low volume ≤ 31, high volume ≥ 32) provided core data for recalculation. The 
overall results of this analysis revealed an OR of 0.85 (95% CI 0.72–0.99; p = 0.00; I2 = 87%). 
Conclusions Despite the shortcomings of this study, the mortality rate was lower in hospitals 
with a larger caseload. Limitations of the meta-analysis are the not uniform cutoff values 
and uncertainty about case mix.
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IntroductIon
Caseload in relation to outcome has been a topic of an increasing number of publications 
in the medical literature. Hospital volume and outcome are generally more strongly 
associated for medical conditions that require more complex management.15,35 Regulations 
for centralization of specialized care are emerging from the medical field, government, and 
health insurance companies. For treatment of patients with ruptured cerebral aneurysms, a 
complex disease, several studies with contrasting results have appeared.6,7,16 The purpose of 
this study was to perform a meta-analysis to investigate the relationship between caseload 
and outcome in series of patients undergoing treatment of aneurysms after subarachnoid 
hemorrhage (SAH). The treatment modality could be either clipping or coiling. Hospital 
mortality was chosen as the outcome measure.
methods
The meta-analysis was constructed according to the MOOSE (meta-analysis of observational 
studies in epidemiology) guidelines.37 An independent experienced librarian searched the 
literature published in MEDLINE, Embase, and the Cochrane Library through September 
28, 2012, using the following key words: SAH, case load, outcome, aneurysm. No language 
restrictions were used. For a detailed search string please see Table 2.1. Studies were eligible 
for inclusion if they met the following criteria: 1) evaluated in-hospital mortality after 
open and/or endovascular treatment in patients with ruptured intracranial aneurysms, 2) 
compared low-volume with high-volume hospitals, and 3) provided an odds ratio or core 
data to calculate an odds ratio. If the same data were used in more than one article, the 
most recent or largest data set was included. Duplicate papers were removed. Conference 
abstracts, reviews, editorials, meta-analyses, and animal studies were also excluded. Studies 
were excluded if they did not provide postoperative mortality rates in patients treated for 
ruptured aneurysms with endovascular coiling or surgical clipping in relation to volume. Two 
researchers (M.v.A. and H.D.B.) independently reviewed the titles and abstracts of the articles. 
In the case of disagreement during this process, a third reviewer (J.d.V.) was asked. From 
the remaining articles, full-text versions were obtained and were independently evaluated 
by the same researchers. From the full-text versions, reference screening was performed 
to evaluate other possible studies. A data recording form, developed for this purpose, was 
used by 2 authors (M.v.A. and R.B.) for independent data extraction from each study. After 
extraction, data were reviewed and were compared by the first author. Disagreement was 
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solved by consensus. Assessment of the methodological quality of the studies included in 
the review was done according to the GRADE guidelines.14 The studies were independently 
assessed by the 2 researchers (R.B. and J.d.V.) for limitations, indirectness, inconsistency, 
imprecision, and publication bias. Overall in-hospital mortality after open surgical and/or 
endovascular treatment in patients with SAH was defined as the primary end point.
Table 2.1 Search strategy and results of MEDLINE, Embase, and Cochrane Library searches*
Results
Step Search Pubmed Cochrane Embase
1 subarachnoid hemorrhage[Mesh:noexp] 14,980 375 26,035
2 subarachnoid haemorrhage[tiab] OR (subarachnoid[tiab] 
AND hemorrhage[tiab]) OR subarachnoid 
hemorrhage[tiab] OR subarachnoid haemorrhages[tiab] 
OR subarachnoid hemorrhages[tiab] OR SAH[tiab] 
OR SAHs[tiab] OR subarachnoid hematoma[tiab] OR 
subarachnoid bleeding[tiab]
17,916 930 22,474
3 Step 1 OR Step 2 22,212 1,214 31,404
4 intracranial aneurysm[Mesh] 19,901 333 23,962
5 (brain aneurysm[tiab] OR brain aneurysms[tiab] OR 
cerebral aneurysm[tiab] OR cerebral aneurysms[tiab])
4,006 372 5,034
6 Step 4 OR Step 5 20,790 492 30,331
7 rupture*[tiab]† 86,436 2,304 102,580
8 Step 6 AND Step 7 5,423 193 4,981
9 Step 3 OR Step 8 24,675 985 33,626
10 “neurosurgery/statistics and numerical data”[mesh]‡ 1,923 13 964
11 workload[Mesh] 13,778 487 24,873
12 high volume[tiab] OR high volumes[tiab] OR high-
volume[tiab] OR higher volume[tiab] OR higher volumes[tiab] 
OR low volumes[tiab] OR lower volumes[tiab] OR low-
volume[tiab] OR lower-volume[tiab] OR workload[tiab] 
OR (work[tiab] AND load[tiab]) OR caseload[tiab] OR 
caseloads[tiab] OR surgeon volume[tiab] OR workloads[tiab] 
OR surgical volume[tiab] OR operative volume[tiab] OR 
surgical volumes[tiab] OR operative volumes[tiab] OR 
(case[tiab] AND load[tiab]) OR case volume[tiab] OR case 
volumes[tiab] OR operation rate[tiab] OR operation rates[tiab] 
OR hospital volume[tiab] OR hospital volumes[tiab] OR 
highest-volume[tiab] OR highest-volumes[tiab]
42,833 24,767 56,421
13 Step 10 OR Step 11 OR Step 12 54,269 24,778 71,050
14 Step 9 AND Step 13 76 35 152
* MeSH = Medical Subject Headings; noexp = no explosion of MeSH heading; tiab = title/abstract.
† The asterisk in this field indicates that rupture was a major topic of these articles.
‡ Quotation marks indicate that the entire phrase was searched.
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statistical analysis
To identify potential associations between hospital volume and mortality, a pooled odds ratio 
with 95% confidence intervals was constructed. The significance of the overall odds ratio 
was determined by the z-test. The Type I error was set at 0.05. The tests were 2-tailed. The 
random effects model was used as the preferable approach to manage potential between-
study heterogeneity. Statistical heterogeneity across studies was quantified using the I2 
statistic. This statistic describes the percentage of total variation across studies that is due 
to heterogeneity rather than chance.19 The I2 statistic was calculated from Q (the Cochran 
heterogeneity statistic) as follows: I2 = 100% × (Q − df)/Q. For sensitivity analysis, each study 
was removed in turn from the total, and the remaining studies were reanalyzed to identify 
the impact of each study on the overall result. Publication bias was graphically assessed using 
a funnel plot. In addition, Egger’s test was used for quantitative assessment. Comprehensive 
Meta-Analysis software (version 2.2.046, BIOSTAT) was used for statistical analysis.
results
Included studies
The initial search revealed 263 studies (Table 2.1). After removing duplicate studies, 
abstracts from 211 studies, including one found by reference screening,36 were evaluated. 
One hundred seventy-nine studies were excluded because they did not meet inclusion 
criteria. Thirty-two studies were considered for full-text evaluation.1–13,16–18,20–23, 25–27,30–34,36,38–40 
Twenty-eight studies were excluded for the following reasons: 2 were review studies,34,40 5 
had insufficient data,5,8,10,36,39 3 included treatment of unruptured aneurysms,3,21,33 8 contained 
single-center data,4,6,11–13,22,30,31 3 had no caseload comparison,18,25,26 2 did not have mortality 
as an outcome,1,20 1 was an editorial,17 3 had overlapping source data,2,7,32 and 1 included 
only patients older than 65 years.38 Therefore, 4 studies were included for final analysis 
(Figure 2.1).9,16,23,27 The selected studies involved a total of 36,600 patients. Retrospective 
data from databases were used in 3 studies, and 1 evaluated data from a survey (Table 2.2). 
The treatment modality was clipping or endovascular coiling in 3 studies, and 1 study 
only evaluated open surgical results. Hospital volume definitions differed between studies. 
Cutoffs and dichotomizations were used as well as division in quartiles. Low volume was 
defined as 9 or fewer patients yearly in 1 study and as fewer than 30 in another. Similarly, 
high volume was defined as more than 20 patients annually in 1 study and as more than 
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Figure 2.1 Chart showing the results of the literature search.
     
  
     
   
      
  Records screened 
n = 211
      
    
   
    
   
     
  
     
  
 
Pubmed n = 76
Cochrane n = 35
Embase n = 152
Additional records identied
through reference screening
n = 1
Records after duplicates removed
n = 211
Records excluded n = 179
Full-text articles assessed
for eligibility
n = 32
Studies included in
qualitative synthesis
n = 4
Studies included in
quantitative synthesis
n = 4
Articles excluded n = 28
Review articles n = 2
Insucient data n = 5
Unruptured aneurysms n = 3
Single centre data n = 8
No caseload comparisson n = 3
No mortality outcome n = 2
Editorial n = 1
Overlapping data n = 3
Only elderly patients n = 1
Table 2.2 Characteristics of the studies
Definition of Vol
Authors & Year Source, Years Treatment modality Low High
Johnston, 2000 University Health Systems 
Consortium, 1994–1997
Clipping & coiling 0–16 
(1th quartile)
> 45 
(4th quartile)
Cross et al., 2003 Database (California & 
Florida), 1998–2000
Clipping & coiling 0–9 
(1th quartile)
36–158 
(4th quartile)
Hattori et al., 2007 Survey Japan, 2003 Clipping < 30 
(1th group)
≥ 50 
(3rd group)
Leake et al., 2011 Nationwide Inpatient 
Sample (NIS) database, 
2001–2008
Clipping & coiling ≤ 20 > 20
50 patients annually in another. The definitions used in the articles were used for primary 
analysis. The methodological quality of 3 articles was graded as low and 1 as very low. Up-
rating was not performed (Table 2.3).
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meta-analysis
The overall meta-analysis suggested a significant relationship for in-hospital mortality for 
SAH patients in favor of high-volume hospitals (OR 0.77 [95% CI 0.60–0.97] random model) 
(Figure 2.2A). The Q value for the test of heterogeneity was 33.2 (p = 0.0001), indicating 
heterogeneity and justifying the use of the random effects analysis. The sensitivity analysis 
revealed a relative weight of the study by Hattori et al.16 Including this study and subsequently 
removing others by alternation lifted the point estimate slightly upward. The result was not 
statistically significant. However, removal of this study with very low quality (see Table 2.3) 
increased the effect size to an OR 0.68 (95% CI 0.56–84) (Figure 2.2B).7 The funnel plot 
suggested publication bias; however, the Egger’s test (intercept 1.21, p = 0.86 [2-tailed]) 
did not (Figure 2.3). This result should be interpreted with great caution, because of the 
very limited number of studies. For comparability between studies, recalculation was done 
with dichotomized data if available (Table 2.4). Cross et al. (low volume ≤ 18 patients, high 
volume ≥ 19 patients) and Johnston (low volume ≤ 31 patients, high volume ≥ 32 patients) 
Figure 2.2 Forest plots showing results of the meta-analysis of high versus low volume hospitals (A) and 
sensitivity analysis (B). 
The squares indicate the mean, the whiskers indicate the 95% CI, and the diamonds indicate the pooled 
estimate (the width of the diamond represents the 95% CI).
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Johnston, 2000 0 0,690 0,550 0,865 -3,209 0,001
Cross et al., 2003 0,586 0,517 0,664 -8,381 0,000
Hattori et al., 2007 1,100 0,915 1,322 1,016 0,310
Leake et al., 2011 0,786 0,719 0,859 -5,323 0,000
0,029-2,1900,9720,604767,0Overall 
0,5 1 2
Favours high volume Favours low volume
A: Meta-analysis high versus low volume hospitals
Study name Statistics with study removed Odds ratio (95% CI) 
with study removedLower Upper 
Point limit limit Z-Value p-Value
Johnston, 2000 2000 0,791 0,588 1,065 -1,546 0,122
Cross et al., 2003 0,843 0,665 1,070 -1,401 0,161
Hattori et al., 2007 0,684 0,555 0,842 -3,574 0,000
Leake et al., 2011 0,762 0,512 1,133 -1,345 0,179
0,767 0,604 0,972 -2,190 0,029
0,5 1 2
Favours high volume Favours low volume
B: Sensitivity analysis
Overall 
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provided core data for recalculation.9,23 The overall results of this analysis of the 4 studies 
revealed an OR of 0.85 (95% CI 0.72–0.99).
dIscussIon
This meta-analysis demonstrates that treatment of patients with ruptured intracranial 
aneurysms in high-volume centers is associated with lower in-hospital mortality compared 
with low-volume centers. The positive correlation between a high-volume center and 
outcome could be attributed to several factors. First of all, high-volume centers more likely 
have a subspecialized team working in a multidisciplinary setting. A well-functioning 
and experienced team consisting of neurologists, neurosurgeons, neuroradiologists, 
neurointerventionalists, neurorehabilitation specialists, neurointensivists, and a dedicated 
nursing team will certainly contribute to a better outcome.5,8,24 A potential drawback of 
centralization would be the risk of rehemorrhage and death during transfer; however, as 
investigated by Bardach et al., the organization of SAH care in high-volume hospitals is 
justified not only for costeffectiveness but also for patient outcome.1 
Several limitations of this study should be mentioned. First, the study data mainly rely 
on retrospective data based on hospital coding and can therefore be biased. Second, the 
patients within the studies were a selection of a population mainly from northern US 
Figure 2.3 Funnel plot. 
The points correspond to the treatment effects from individual studies, the diagonal lines show the expected 
95% confidence intervals around the summary estimate. Odds ratios are plotted on a logarithmic scale.
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databases. Infrastructural and geological characteristics might not be applicable to other 
countries. Third, the treatment modality might be associated with outcome and with hospital 
volume; centers also providing endovascular treatment have better results because of the 
lower associated morbidity and mortality rates as found in the International Subarachnoid 
Aneurysm Trial (ISAT) and recently the Barrow Ruptured Aneurysm Trial (BRAT).28,29 
High-volume centers are more likely to have an endovascular treatment modality and thus 
will probably have better results.9,13 Fourth, we used unadjusted core data from the studies to 
attain comparability, since adjustment for case mix was not done or it was done in different 
ways. Hattori et al. corrected for initial clinical grade, but not for comorbidities and did not 
find a significant difference in the distribution of the World Federation of Neurosurgical 
Societies grade on admission between the different volume groups.16 Cross et al. corrected 
for comorbidities but not for initial grade.9 Leake et al. did not correct for comorbid 
conditions nor initial grade.27 Johnston corrected for age but not for comorbidities or initial 
grade.23 Fifth, the distinction between low volume and high volume is artificial. As shown, a 
uniform cutoff is not provided. At best, an approximate cutoff could be estimated. However, 
recalculation with dichotomized data revealed comparable results, centering the possible 
distinction between high volume and low volume around 20–30 patients yearly. Sixth, in-
hospital mortality was chosen as the primary outcome measure; although commonly used 
as a measure of quality of care, it can be influenced by discharge policies. Better would be a 
more detailed outcome measure such as the modified Rankin Scale score; unfortunately, only 
the study by Hattori et al. provided these data.16 Finally, transfer of patients might cause bias. 
Patients who were likely to die were not transferred to a high-volume center for treatment; 
conversely, transferred patients tended to do better than patients in community hospitals.13,41
This study does not answer the question of how much patients should be treated by a single 
surgeon or neurointerventionalist to obtain the best result.3,26,39 As previously stated, the 
results of treatment are not merely the merits of one specialist but the chain of care. In the 
scope of quality of care and the increasing demand for centralization, volume number alone 
is not sufficient as a parameter to guide these developments. Caseload should be seen as 
one of the cofactors related to outcome. 
conclusIons
Despite shortcomings of the included studies but based on the best available data at this 
moment, mortality is lower in hospitals that treat a high volume of patients with SAH. 
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Although a true cutoff value to distinguish between high- and low-volume centers could not 
be given, it probably can be centered between 20 and 30 patients annually. An explanation 
for the relationship between outcome and caseload could be a multidisciplinary approach 
resulting in a team dedicated to the care of patients with SAH. As such, the number of treated 
patients yearly cannot be used as a sole measure for quality of care. 
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AbstrAct
Background Several studies have included different comorbid conditions in prediction 
models for stroke patients. For subarachnoid haemorrhage (SAH), it is not known whether 
the Charlson Co-morbidity Index (CCI) is associated with outcome. We evaluated if this 
index was associated with outcome in patients with ruptured intracerebral aneurysms.
Methods The data of all consecutive aneurysmal SAH (aSAH) patients treated at the 
Radboudumc, Nijmegen, The Netherlands and entered in the database were retrospectively 
analysed. Clinical condition at admission was recorded using the WFNS (World Federation 
of Neurological Surgeons Grading System) grade was collected, as were the age and treatment 
modality. The burden of co-morbidity was retrospectively registered using the CCI. Outcome 
was dichotomised on the modified Rankin Scale (mRS; 0–2, favourable outcome; 3–6, 
unfavourable outcome). A binary logistic regression analysis was performed.
Results Between 6th May 2008 and 31st July 2013, 457 patients were admitted because of 
non-traumatic SAH (aSAH). Seventy-seven (16.8%) patients had no aneurysm. Of the 380 
patients with aSAH, information on co-morbid conditions was available for 371 patients. 
Thirty-six of those 371 had no treatment because of: bad clinical condition in 34 (9.2%), 
a non-treatable dissecting aneurysm in 1 (0.3%) and the explicit wishes of another. Co-
morbidity was present in 113 (31.5%) patients. Binary logistic regression analysis revealed 
no added value of using the CCI in predicting the outcome (p = 0.91). 
Conclusions This study reports that the CCI is not associated with the outcome classified 
on the mRS at 6 months in patients after aSAH. The CCI has no added value in case-mix 
correction.
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IntroductIon
The Charlson Co-morbidity Index (CCI) is an index used to weight co-morbid conditions 
in predicting mortality.3 Depending on the strength of the relationship with mortality, 
between 1 and 6 points are assigned to a set of co-morbidities.8 The CCI has been evaluated 
for use in cases of intracerebral haemorrhage and ischaemic stroke, but not for aneurysmal 
subarachnoid haemorrhage (aSAH).1,8 Co-morbid conditions can, however, influence the 
outcome in SAH.4–6,9,11,13,15,19 Aneurysmal SAH is a distinct group of stroke patients, in 
which perhaps other co-variables should be taken in to account when assessing the weight 
of the CCI. A recent review of prediction models in aSAH revealed the most commonly 
identified and valuable patient factors that are associated with outcome; namely, age and 
initial condition at presentation.10 Treatment modality (endovascular coiling or clipping) 
is also known to influence outcomes.12,14 The purpose of this study was to evaluate whether 
the CCI is associated with a 6-month functional outcome in aSAH.
methods
Retrospectively, the data of all consecutive aSAH patients treated in the Radboudumc, 
Nijmegen, The Netherlands from May 6th 2008 to July 31st 2013 were analysed. Clinical 
condition at admission as recorded by the WFNS (World Federation of Neurological Surgeons 
Grading System) scale was used in analysis, as were treatment modality and age.7,21 The 
primary outcome was recorded using the modified Rankin Scale (mRS) after 6 months, 
because of protocolised combined imaging and clinical follow-up after the same period. 
The co-morbidities were extracted from the electronic patient files. The total CCI score for 
each patient was computed and four categories of co-morbidity were defined as previously 
used by others: 0 (none), 1 (moderate), 2 (severe) and 3 or higher (very severe).1,20 The study 
was approved by the institutional review board. The results are reported according to the 
STROBE statement guidelines.22 
statistical analysis
A binary logistic regression analysis was performed using the mRS score as a dichotomised 
variable (0–2, favourable outcome; 3–6, unfavourable outcome). SPSS (version 20; SPSS, 
Chicago, IL, USA) was used for the statistical analysis and the significance was considered 
to be p < 0.05.
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results
Between 6th May 2008 and 31st July 2013, 457 patients were admitted because of a non-
traumatic SAH (aSAH). Seventy-seven (16.8%) patients had no aneurysm. Of the 380 
patients with aSAH, eight (2.1%) did not have a follow-up because they returned to their 
home country. One (0.3%) patient had no information on his co-morbid condition, meaning 
that analysis was possible for 371 patients. Thirty-six of those 371 had no treatment (Figure 
3.1). Treatment was preferentially endovascular in patients with aneurysms equally suitable 
for clipping or coiling. The last follow-up was 1st February 2014. The characteristics of the 
patients are set out in Table 3.1, while the frequency of each co-morbidity is provided in 
Table 3.2. The distribution of the CCI sum-scores is given in Figure 3.2, and is categorised 
according to severity within each outcome group in Table 3.3. Co-morbidity was present in 
113 (31.5%) patients. There were no differences in CCI frequency distribution within the two 
outcome (mRS) categories (Pearson chi-squared test p = 0.084). A binary logistic regression 
analysis revealed no beneficial use of the CCI in predicting outcome (odds ratio, 1.020; p 
= 0.91) (Table 3.4). In this model, strong predictors of outcome were initial grade (WFNS), 
age and treatment modality (area under the receiver operating characteristic curve, 0.86; 
SE, 0.02). In a sub-analysis using no versus any co-morbidity, no added value was found 
(p = 0.95). An ordinal regression analysis using non-dichotomised mRS outcomes did not 
change the previous findings.
Figure 3.1 Flowchart for the progression of 457 patients admitted because of non-traumatic 
subarachnoid haemorrhage (SAH).
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Table 3.1 Patient characteristics
Variable n (%)
Sex
Male
Female
115 (31.0)
256 (69.0)
Age, mean [SD] 55.4 [13.2]
WFNS
I
II
III
IV
V
133 (35.8)
82 (22.1)
15 (4.0)
80 (21.6)
61 (16.4)
Treatment modality
Clip
Coil
Not treated
67 (18.1)
268 (72.2)
36 (9.7)
n = number of patients; SD = standard deviation; WFNS = World Federation of Neurological Surgeons Grading 
System for SAH.
Table 3.2 Charlson Co-morbidity Index (CCI) categories in aneurysmal subarachnoid haemorrhage
Condition CCI weight Total frequency, n (%)
Myocardial infarct 1 11 (3.0)
Congestive heart failure 1 0 (0.0)
Peripheral vascular disease 1 15 (4.0)
Cerebrovascular disease 1 28 (7.5)
Dementia 1 0 (0.0)
Chronic pulmonary disease 1 30 (8.1)
Connective tissue disease 1 12 (3.2)
Ulcer disease 1 0 (0.0)
Mild liver disease 1 2 (0.5)
Diabetes 1 18 (4.9)
Diabetes with end-organ damage 2 0 (0.0)
Hemiplegia 2 2 (0.5)
Moderate or severe renal disease 2 6 (1.6)
Any tumour 2 21 (5.7)
Leukaemia 2 2 (0.5)
Lymphoma 2 0 (0.0)
Moderate or severe liver disease 3 0 (0.0)
Metastatic solid tumor 6 1 (0.3)
AIDS/HIV 6 0 (0.0)
AIDS = acquired immune deficiency syndrome; HIV = human immunodeficiency virus.
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Figure 3.2 Distribution of the Charlson Co-morbidity Index (CCI) sum-scores.
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Table 3.3 Cross-tabulation Charlson Co-morbidity Index (CCI) categories by dichotomised modified 
Rankin Scale (mRS)
CCI
mRS
Total0–2 3–6
0 167 (72.6%) 91 (64.5%) 258 (69.5%)
1 39 (17.0%) 29 (20.6%) 68 (18.3%)
2 18 (7.8%) 10 (7.1%) 28 (7.5%)
≥ 3 6 (2.6%) 11 (7.8%) 17 (4.6%)
Total 230 (100%) 141 (100%) 371 (100%)
Percentages are given within mRS group.
Table 3.4 Odds ratios for variables in outcome analysis using binary logistic regression analysis. Higher 
odds ratio is related to worse outcome in dichotomised mRS
Variable Odds ratio Level of sign (p value)
Aage 1.052 0.00
WFNS* 2.067 0.00
CCI 1.020 0.91
Treatment (coil) 1.000 0.00
Treatment (clip) 2.205 0.02
Treatment (none) 47.544 0.00
Treatment reference group is coiling.
WFNS = World Federation of Neurological Surgeons grading system for SAH; CCI = Charlson Co-morbidity 
Index sum score.
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dIscussIon
The CCI for co-morbid conditions is not associated with the outcome at 6 months in 
aSAH in these data. The value of the CCI for acute ischaemic stroke and non-traumatic 
(non-aneurysmal) intracerebral haemorrhage (ICH) is often reported.1,8,20 Stroke patients 
are generally much older, with a mean age of over 70 years, compared with aSAH patients 
in general and this cohort in particular (mean age, 55.4)20,25 (Table 3.1). Increased age is 
associated with the increased prevalence of co-morbidities, and strokes share risk factors 
with many chronic diseases (e.g. myocardial infarction, diabetes).20 Several limitations of 
this study have to be noted. First, the chart review was conducted retrospectively. However, 
studies including co-morbidity frequently rely on administrative hospital (coding) data that 
are retrospectively gathered.4,6 Secondly, the analysis was carried out on 371 patients. If the 
investigated group of patients were larger, it is possible that there would have been a small 
significant result. Thirdly, the CCI was developed to predict 1-year mortality, but in our series 
we evaluated outcome at 6 months because of protocolised imaging and clinical follow-up. 
Recent studies have revealed that a minority of patients improve between 6 and 12 months.23
Contrasting reports have appeared for co-morbid conditions in aSAH.1,4–6,8,13,18,19,24 Using 
administrative databases, O’Kelly et al.16 found a significant increase in the hazards of death 
and re-admission for SAH per unit increase on the Deyo adaptation of the CCI (HR, 1.14 
[1.08–1.21]; p < 0.001) in a retrospective cohort of 3,120 patients. Other reports evaluated 
several individual co-morbid conditions in relation to outcome for aSAH with predominantly 
negative or contrasting results (see Supplemental Table S3.1, which illustrates the value of 
co-morbidity in aneurysmal SAH reported in the literature). Meanwhile, Langham et al.11 
found a significant contribution of any co-morbid condition to outcome, which was defined 
as death or severe disability at 6 months, in a cohort of 2,397 patients (univariate, 1.87 
[1.56–2.25], p < 0.001; multivariate, 1.46 (1.20–1.78), p = 0.0003). In the Langham report, 
the CCI itself was not used, and other co-morbid conditions like hypertension (not part of 
the CCI) were included. Finally, in their retrospective study of the treatment of ruptured 
and unruptured aneurysms, Cowan et al.4 found that co-morbid conditions (not specifically 
in the form of CCI) were significant predictors of death (OR, 1.08 [1.04–1.12], p < 0.001, 
for each condition increase). 
For a comparison of outcome in the treatment of aSAH, case-mix correction is essential. 
A major clinical variable is initial grade as evaluated by the WFNS scale. The odds ratio 
associated with WFNS is reported to be between 2.14 and 13.51 depending on the grade.17,18 
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De Toledo found a relative risk for poor outcome (Expβ) dependent on the WFNS scale 
of 3.43–78.1. An often reported co-morbid condition associated with bad outcome is 
hypertension, but this is not included in the CCI.5,13,18,19
Due to the evolving interest in healthcare outcomes overall, the registration burden is growing 
enormously. To increase data entry by healthcare providers, focusing on items of significant 
interest is of utmost importance. This study will contribute to the selection of items that are 
relevant for outcome measurement of SAH; strong predictors of outcome were initial grade, 
age and treatment modality. Regarding treatment modality, we had a relatively high ratio 
of endovascular treated patients. According to a European internet survey, high-volume 
centres have a significantly higher proportion of coiled ruptured aneurysms in comparison 
with low-volume centres.2 Within these high volume centres, we are at the high end of the 
spectrum of proportion coiled aneurysms. We showed that the CCI as a whole set of co-
morbidity parameters is not associated with clinical outcome.
conclusIons
This study reports that the CCI is not associated with the outcome classified on the mRS 
at 6 months in patients after aSAH. The CCI has no added value in case-mix correction. 
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supplement
Supplemental Table S3.1 Reported value of co-morbidity in aneurysmal SAH in literature
                       Author, year
Condition
Cowan 
et al., 
20031
Cross 
et al., 
20032
Crowley 
et al., 
20093
Mocco 
et al., 
20064
Rosen 
et al., 
20045
Rosengart 
et al., 
20076
Zacharia 
et al., 
20097
Myocardial infarct NS Sign - NS - NS -
Congestive heart failure NS Sign NS NS - - -
Peripheral vascular disease NS - - - - - -
Cerebrovascular disease NS - - NS - - -
Dementia NS - - - - - -
Chronic pulmonary disease Sign NS NS - - - -
Connective tissue disease NS - - - - - -
Ulcer disease NS - - - - - -
Mild liver disease NS - Sign - NS NS -
Diabetes NS NS NS NS NS NS Sign
Diabetes with end-organ 
damage
NS NS NS NS NS NS -
Hemiplegia NS - - - - - -
Moderate or severe renal 
disease
Sign - NS NS - - -
Any tumor NS - - - - - -
Leukemia NS - - - - - -
Lymphoma NS - Sign - - - -
Moderate or severe liver 
disease
NS - - - NS NS -
Metastatic solid tumor NS NS NS - - - -
AIDS/HIV NS - NS - - - -
Sign = statistically significant; NS = statistically not significant; - = not evaluated; AIDS = Acquired Immune 
Deficiency Syndrome; HIV = Human Immunodeficiency Virus.
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AbstrAct
Object Aneurysmal rerupture prior to treatment is a major cause of death and morbidity in 
aneurysmal subarachnoid hemorrhage. Recognizing risk factors for aneurysmal rebleeding 
is particularly relevant and might help to identify the aneurysms that benefit from acute 
treatment. It is uncertain if the size of the aneurysm is related to rebleeding. This meta-
analysis was performed to evaluate whether an association could be determined between 
aneurysm diameter and the rebleeding rate before treatment. Potentially confounding 
factors such age, aneurysm location, and the presence of hypertension were also evaluated.
Methods The authors systematically searched the PubMed, Embase, and Cochrane data-
bases up to April 3, 2013, for studies of patients with aneurysmal subarachnoid hemorrhage 
that reported the association between aneurysm diameter and pretreatment aneurysmal 
rebleeding. The Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) criteria were used to evaluate study quality.
Results Seven studies, representing 2,121 patients, were included in the quantitative analysis. 
The quality of the studies was low in 2 and very low in 5. Almost all of the studies used 10 
mm as the cutoff point for size among other classes, and only one used 7 mm. An analysis was 
performed with this best unifiable cutoff point. Overall rebleeding occurred in 360 (17.0%) 
of 2,121 patients (incidence range, from study to study, 8.7%–28.4%). The rate of rebleeding 
in small and large aneurysms was 14.0% and 23.6%, respectively. The meta-analysis of the 
7 studies revealed that larger size aneurysms were at a higher risk for rebleeding (OR 2.56 
[95% CI 1.62–4.06]; p = 0.00; I2 = 60%). The sensitivity analysis did not alter the results. 
Five of the 7 studies reported data regarding age; 4 studies provided age-adjusted results 
and identified a persistent relationship between lesion size and the risk of rebleeding. The 
presence of hypertension was reported in two studies and was more prevalent in patients 
with rebleeding in one of these. Location (anterior vs posterior circulation) was reported 
in 5 studies, while in 4 there was no difference in the rebleeding rate. One study identified 
a lower risk of rebleeding associated with posterior location aneurysms. 
Conclusions This meta-analysis showed that aneurysm size is an important risk factor 
for aneurysmal rebleeding and should be used in the clinical risk assessment of individual 
patients. The authors’ results confirmed the current guidelines and underscored the 
importance of acute treatment for large ruptured aneurysms.
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IntroductIon
The incidence of aneurysmal subarachnoid hemorrhage (SAH) is about 5–10 cases per 
100,000.21,26 Closure of the aneurysm after initial SAH is the primary goal to prevent 
aneurysmal rebleeding, which has an associated mortality rate of up to 50%.32 The incidence 
of rebleeding after an SAH has been estimated to be 14%–17% during the first 24 hours, and 
studies have shown that 87%–92% of all rebleeding occurs within the first 6 hours after the 
initial bleed.9,32 Endovascular coiling or clipping to secure the aneurysm is advised as early 
after rupture as is feasible to reduce the rate of rebleeding.8 Currently, ultra-early treatment, 
considered to be within 24 hours, is advised for patients in good clinical condition.34 Although 
nonmodifiable causes, such as transfer from other hospitals and late diagnosis, might delay 
treatment, ultra-early treatment can also be difficult due to internal logistics issues like limited 
24/7 surgical coverage and access to operating theaters and anesthetic and nursing staff.34
Recognizing risk factors for aneurysmal rebleeding is particularly relevant and might help 
to identify the aneurysms that benefit from acute treatment. In recent years, several risk 
factors, such as hypertension and the location and size of the aneurysm, have been shown 
to be associated with rebleeding.9,10,19,28,37 Biomechanical studies have indicated that cerebral 
aneurysmal rupture occurs when there is a decrease in the ratio of the artery wall thickness 
to the radius of the aneurysm.7 This concept might explain the possible relationship between 
aneurysm diameter and the risk of rebleeding. However, the association between the risk of 
rebleeding and aneurysm size might be confounded by age.28 In particular, older patients 
may have larger aneurysms, and their general condition makes it more likely that treatment 
is postponed, leaving these individuals more prone to rebleeding. This meta-analysis was 
performed to evaluate whether an association could be established between aneurysm 
diameter and rebleeding rate before treatment. Potentially confounding factors like age, 
aneurysm location, and the presence of hypertension were also evaluated.
methods
search strategy and selection criteria
The meta-analysis was constructed using the MOOSE guidelines.38 In particular, an 
independent, experienced librarian systematically searched the PubMed, Embase, and 
Cochrane databases up to April 3, 2013, for studies of patients with aneurysmal SAH 
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that reported the association between aneurysm diameter and pretreatment aneurysmal 
rebleeding. The search strategy is set out in Table 4.1.
data extraction
Two authors (J.V.L. and H.B.) independently read all titles and abstracts and selected those 
that appeared to be relevant for a full text review without language restrictions. Conference 
abstracts, reviews, meta-analyses, editorials, and animal studies were excluded. From the 
remaining studies, full-text articles were obtained and independently evaluated by two 
of the authors (J.V.L. and H.B.). Studies were deemed to be eligible if they included: 1) 
patients with SAH in either a prospective or retrospective population-based design; 2) the 
association between aneurysm diameter and the rebleeding rate; and 3) results that included 
or enabled the calculation of an odds ratio. A third author (R.B.) was consulted to resolve any 
disagreements. Reference screening was conducted to identify additional studies from the 
full-text articles that were evaluated. Included studies were selected for a quality review. The 
Table 4.1 Search strategy and results in Pubmed, EMBASE and Cochrane databases
No. of studies
Step Search terms Pubmed                        Embase Cochrane
1 subarachnoid haemorrhage.ti,ab. OR Subarachnoid 
Hemorrhage[Mesh:noexp] OR (subarachnoid.ti,ab. AND 
hemorrhage.ti,ab.) OR subarachnoid hemorrhage.ti,ab. 
OR subarachnoid haemorrhages.ti,ab. OR subarachnoid 
hemorrhages.ti,ab. OR SAH.ti,ab. OR SAHs.ti,ab. OR 
subarachnoid hematoma.ti,ab. OR subarachnoid bleeding.
ti,ab. OR ((Brain Aneurysm.ti,ab. OR brain aneurysms.
ti,ab. OR Cerebral Aneurysm.ti,ab. OR cerebral Aneurysms.
ti,ab. OR "Intracranial Aneurysm"[Mesh]) AND (rupture*.
ti,ab.)))))†‡
25,423 35,627 998
2 ("Recurrence"[Mesh] OR Recurrence.ti,ab. OR Recurrences.
ti,ab. OR Rebleed*.ti,ab.)
306,816 339,678 21,206
3 Step 1 AND Step 2 1,844 2,151 75
4 ("Risk"[Mesh] OR Risk.ti,ab. OR sized.ti,ab. OR sizes.ti,ab. OR 
10 mm.ti,ab. OR 7 mm.ti,ab. OR 5 mm.ti,ab. OR 6 mm.ti,ab. 
OR 8 mm.ti,ab. OR 9 mm.ti,ab. OR diameter.ti,ab.)
1,849,179 2,355,608 111,279
5 Step 3 AND Step 4 610 773 25
6 Limits: none 610 773 25
MeSH = Medical Subject Headings; mm = millimeter; noexp = no explosion of MeSH heading; ti,ab = title/abstract.
† The asterisk in this field indicates that rupture was a major topic of these articles.
‡ Quotation marks indicate that the entire phrase was searched.
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methods recommended by the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) system for rating the quality of evidence were applied.2,11–17 The ORs 
and 95% CIs between small and large intracranial aneurysms were extracted or calculated. 
Size categories were then registered. The cutoff between small and large size had to be 
established according to the published data. In cases of overlapping cohorts, we excluded 
the one with the lesser-quality data or, if equal in quality, the one with the fewest patients 
to prevent an artificial increase in effect size.
statistical analysis
Comprehensive Meta-Analysis software (Version 2.2.046, 2007, Biostat, Inc.) was used to 
perform statistical analysis. The odds ratio for the risk of the rebleeding of small compared 
with large intracranial aneurysms was used as the effect size. Size cutoff was determined based 
on the presence of a (close to) common value across the studies. Both fixed- and random-
effect models were used to calculate the summary ORs and 95% CIs. The significance of 
the overall OR was determined using a Z-test. For the sensitivity analysis, each study was 
removed from the total and the remaining studies were reanalyzed. The Type I error was set 
at 0.05 and the tests were 2-tailed. We assessed the heterogeneity between the study estimates 
using the I2 statistic, with thresholds for a low degree of heterogeneity set at 40%.13 The funnel 
plots were inspected, and the Egger test was used to look for evidence of publication bias.
results
Included studies
The literature search revealed a total of 1,408 records: 610 in PubMed, 773 in Embase, and 25 
in the Cochrane database (Figure 4.1, Table 4.1). An additional study was found by screening 
the references. After the removal of duplicates, we were able to identify 867 studies. Review 
of the abstracts left us with 26 studies for the full-text evaluation.3–6,9,10,18–20,22–25,27–31,33,35–37,39,41 
Ten studies were excluded because they did not evaluate aneurysm diameter as a risk 
factor for rehemorrhage rate.4,6,9,18,22,24,29,36,39,41 Two other articles were excluded because 
one was a review and the other was an editorial.25,36 One study was written in Japanese 
and was thus also excluded.31 Four studies used an overlapping cohort, and the one with 
most appropriate data was selected.5,19,20,27,28,30,35 In total we identified 9 studies that met our 
inclusion criteria.3,10,19,23,27,28,33,37,41 Clinical and/or radiological definitions of rebleeding were 
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given in 8 studies and these are listed in Table 4.2. Only 1 study reported the median time to 
rebleeding and the median time to aneurysm repair.3 Aneurysm size categories were given 
in 7 studies, while 2 others reported the mean size for the lesions in the non-rebleeding 
group compared with the rebleeding group (Table 4.2). Four studies reported on time to 
treatment or time to rebleeding (Table 4.2).
Quality assessment
The methodological quality of the 9 included studies was assessed. Of a total of 45 scores, 
there was no disagreement (Table 4.3). As a consequence of their observational design, all 
of the studies started with a maximal quality score of low. None of the studies were rated 
down based on serious inconsistency, indirectness, imprecision, or publication bias. In 5 
studies, however, the quality was rated down because of serious limitations: Adjustment of the 
rebleeding rate for the time after the initial hemorrhage was not performed, or consecutive 
series were not reported.10,19,23,33,37
Figure 4.1 Chart showing the results of the literature search.
Pubmed n = 610
Cochrane n = 25
Embase n = 773
Additional records identiﬁed 
trough reference screening
n = 1
Records after duplicates removed
n = 867
Records screened
n = 867
Records excluded
n = 841
Full-text asessed for eligibility
n = 26
Articles excluded n = 17
Review article n = 1
Insuﬃcient data n = 1
Overlapping data n = 4
Editorial/ Abstract n = 1
Language (Japanese) n = 1
Studies included in qualitative 
synthesis
n = 9
Records excluded 
n = 2
Studies included in quantitative 
synthesis
n = 7  
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data analysis
Seven of 9 studies provided core data, making calculation of the OR possible.10,19,23,28,33,37,41 
Almost all of the studies used 10 mm as the cutoff point for aneurysm size among others 
classes, with only 1 study using 7 mm (Table 4.4). An analysis was performed with this 
best unifiable cutoff point. Overall rebleeding occurred in 360 (17.0%) of 2,121 patients 
(incidence range, from study to study, 8.7%–28.4%). The rate of rebleeding in small and 
large aneurysms was 14.0% and 23.6%, respectively (absolute risk difference 9.6%). The 
meta-analysis of the 7 studies revealed that larger size aneurysms had an overall OR for 
rebleeding of 2.32 (95% CI 1.77–3.04; p = 0.00) and an OR of 2.56 (95% CI 1.62–4.06; p = 
0.00) for a fixed- and a random-effect model, respectively (Figure 4.2 upper). The results 
were subject to heterogeneity, which was determined by the I2 statistic to be 60%, indicating 
that the random-effect the results (Figure 4.2 lower). The funnel plot gave no indication of 
publication bias, but the findings are of limited value because of the small number of studies 
Table 4.4 Rebleeding rates
                                                                      
Authors & Year
Aneurysm size used 
for analysis Rebleeding rate (%)*
Small Large Small Large Total rebleeding
Kassell & Torner, 1983 < 10 mm ≥ 10 mm 49/469 (10.4) 21/195 (10.7) 70/664 (10.5)
Paré et al., 1992 < 10 mm ≥ 10 mm 2/61 (3.3) 13/67 (19.4) 15/128 (11.7)
Beck et al., 2006 NA: reported mean 
size in non-rebleeding 
& rebleeding group; 
6.9 ± 4.7 vs 11.2 ± 9.2 
mm (p = 0.002)
NR NR NA 
Plezier et al., 2006 ≤ 10 mm > 10 mm 68/281 (24.2) 22/73 (30.1) 90/354 (25.4)
Inagawa, 2010 < 10 mm ≥ 10 mm 48/205 (23.4) 33/80 (41.3) 81/285 (28.4)
Guo et al., 2011 ≤ 10 mm > 10 mm 18/169 (10.7) 52/157 (33.1) 70/326 (21.5)
Shiue et al., 2011 < 10 mm ≥ 10 mm 13/195 (6.7) 9/59 (15.3) 22/254 (8.7)
Lord et al.,  2012 NA: reported mean 
size in non-rebleeding 
& rebleeding group; 
7 mm (5–10) vs 8 mm 
(6–15) (p = 0.001)
NR NR NA (case-
control study)
Tsui et al., 2012 < 7 mm ≥ 7 mm 5/75 (6.7) 7/35 (20.0) 12/110 (10.9)
Total NA NA 203/1455 (14.0) 157/666 (23.6) 360/2121 (17.0)
NA = not applicable; NR = not reported.
* The rebleeding rate is the percentage derived by dividing the number of patients with a rebleed by the total 
number of patients.
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considered (Figure 4.3). The Egger regression test revealed an intercept of 2.3 with a 2-tailed 
p value of 0.22, and it was accordingly not statistically significant. Five of the 7 studies 
reported data on age; 4 studies provided age-adjusted results and identified a persistent 
relationship between size and the risk of rebleeding.10,19,28,37 The presence of hypertension 
was reported in 2 studies and was more prevalent in patients with rebleeding in 1 of these 
studies.10,19 Location (anterior vs posterior circulation) was reported in 5 studies, while in 
4 there was no difference in the rebleeding rate.10,19,33,37,41 One study identified a lower risk 
of rebleeding associated with posterior circulation aneurysms.37 These findings provide 
insufficient evidence to relate hypertension and/or location of the aneurysm with the 
rebleeding rate. 
Figure 4.2 Forest plots showing results of the meta-analysis of studies reporting rebleeding risk of large 
versus small aneurysms (upper) and sensitivity analysis (lower). 
The squares indicate the mean, the whiskers indicate the 95% CI, and the diamonds indicate the pooled 
estimate (the width of the diamond represents the 95% CI).
Model Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Kassel & Torner, 1983 1.039 0.603 1.792 0.138 0.890
Pare et al., 1992 7.102 1.532 32.922 2.505 0.012
Machiel Plezier et al., 2006 2.430 1.191 4.956 2.441 0.015
Inagawa, 2010 2.297 1.325 3.981 2.962 0.003
Guo et al., 2011 4.154 2.301 7.502 4.723 0.000
Shiue et al., 2011 2.520 1.019 6.234 2.000 0.045
Wu  et al., 2012 4.333 1.243 15.104 2.302 0.021
Fixed 2.319 1.772 3.036 6.123 0.000
Random 2.562 1.619 4.056 4.015 0.000
0.01 0.1 1 10 100
Favours small aneurysms Favours large aneurysms
Study name Cumulative statistics Cumulative odds ratio (95% CI) 
Lower Upper 
Point limit limit Z-Value p-Value
Kassel & Torner, 1983 1.039 0.603 1.792 0.138 0.890
Pare et al., 1992 2.364 0.367 15.237 0.905 0.366
Machiel Plezier et al., 2006 2.130 0.849 5.342 1.612 0.107
Inagawa, 2010 2.069 1.130 3.790 2.354 0.019
Guo et al., 2011 2.457 1.380 4.376 3.054 0.002
Shiue et al., 2011 2.441 1.493 3.992 3.558 0.000
Wu et al., 2012 2.562 1.619 4.056 4.015 0.000
2.562   1.619 4.056 4.015 0.000
0.01 0.1 1 10 100
Favours small aneurysms Favours large aneurysms
Model
Random
A Meta-Analysis: rebleed risk in large vs small aneurysms 
B Sensitivity-Analysis: rebleed risk in large vs small aneurysms 
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Only a single study evaluated the risk of rebleeding over time dichotomized for size; the 
authors found a difference of rebleeding rate within 24 hours that persisted for 3 days after 
the initial hemorrhage.28 They reported a hazard ratio for large aneurysm of 2.4 (95% CI 
1.2–4.5). In another study, median time to aneurysm obliteration did not differ between 
rebleeding and non-rebleeding groups but was not stratified according to lesion size.3
The use of antifibrinolytic agents was reported only by 1 study; the investigators included 
patients from 1996 to 2011, and from 2003 on, they used, on a routine basis, aminocaproic 
acid for all patients before aneurysm clipping or coiling.27
Conflicting results have been reported regarding the effect of clinical grade on the risk of 
rebleeding. Six studies evaluated Hunt and Hess grade as a factor in relation to rebleeding. 
One study matched for Hunt and Hess grade found a significant difference in aneurysm 
size in those with rebleeding versus those without rebleeding.27 Two studies reported no 
significant association between Hunt and Hess grade and rebleeding risk.32,40 The authors 
of one study concluded that the larger the aneurysm, the worse was the World Federation 
of Neurosurgical Societies grade, but did not report it as a independent risk factor.14 Two 
studies found Hunt and Hess grade to be a statistically significant independent risk factor 
for rebleeding (ORs 2.5 and 4.9).5,7 Clinical grade at admission is a possible independent 
risk factor for rebleeding.
Figure 4.3 Funnel plot. 
The points correspond to the treatment effects from individual studies, the diagonal lines show the expected 
95% confidence intervals around the summary estimate. Odds ratios are plotted on a logarithmic scale.
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dIscussIon
The findings of this meta-analysis show that aneurysm size is an important determinant 
of aneurysmal rebleeding. Age and location are unlikely to be confounding factors. The 
presence of hypertension was insufficiently registered to determine the role of possible 
confounding effects. To reduce rebleeding rates, patients with large aneurysms should, 
when feasible, undergo acute treatment rather than ultra-early treatment, despite possible 
logistical issues. Additionally, if patients are referred from other centers, or if the diagnosis 
is delayed, those with large aneurysms still require urgent treatment because it has been 
shown that the effect size of this association might persist for up to 72 hours after the initial 
bleed.28 An increased risk is seen even within 24 or 48 hours, the time window in which 
most aneurysm are currently treated.25 
The results of this analysis for ruptured aneurysms correspond with those of the ISUIA 
study, in which the primary bleeding risk was greater for individuals with larger unruptured 
aneurysms.40 
The present research has several limitations. First, there is a potential for publication bias; 
studies showing no association between aneurysm diameter and rebleeding rate are less 
likely to be published. The estimated effect size in this meta-analysis could therefore be 
overestimated. Second, the studies considered did not include data from patients who 
had died before hospital admission, and this rate would be estimated to be as high as 
15%.26 Rebleeding rates during transfer to the hospital were also included and may be as 
high as 24%.10 Moreover, the average time to hospital admission varied considerably after 
the initial SAH. Only one study reported median time to aneurysm repair and aneurysm 
rebleeding.10 The research by Machiel Pleizier et al. revealed that there is no significant 
difference between small and large aneurysms when it comes to the risk of rebleeding 
72 hours after the initial SAH.28 Third, only one study reported the use of aminocaproic 
acid.27 Although antifibrinolytic therapy does not improve survival or the chance of 
being independent in activities of daily living, it does reduce the risk of rebleeding by 
approximately 35%, as indicated in a recent Cochrane review.1 Therefore, it is an important 
factor in rebleeding rate; unfortunately, the published studies did not provide data with 
which to evaluate the effects of both size and antifibrinolytic therapy together. Fourth, 
the cutoff for aneurysm size at 10 mm is artificial and chosen based on the categories set 
out in the published literature. Fifth, even if rebleeding is prevented in patients with large 
aneurysms, there is still a substantial rate of rebleeding events (14.0%) in cases involving 
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small aneurysms. Only the acute treatment of all patients is optimal for prevention of 
rebleeding.28
Hypothetically, acute treatment could be associated with additional treatment risks like 
increased intraoperative rupture due to the newly formed instable thrombus. However, 
for treatment within 24 hours, it has been shown that this timeframe was associated with 
improved clinical outcomes, although the benefit was more pronounced for coiling than 
clipping.34 Moreover, it is unlikely that the risks of acute treatment will accrue in such a way 
that they outweigh the very high morbidity and mortality rates associated with rebleeding.
conclusIons
This meta-analysis showed that aneurysm size is an important risk factor for aneurysmal 
rebleeding and should be used in the clinical risk assessment of individual patients. Our 
results confirmed the current guidelines and stressed the importance of acute treatment 
for large ruptured aneurysms.
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AbstrAct
In Europe only few neurosurgeons are trained in both open surgical clipping as well as in 
endovascular techniques for treatment of intracranial aneurysms. To investigate the safety 
and efficacy of performing both techniques we, two dual trained neurosurgeons, analyzed 
our results in repairing ruptured intracranial aneurysms. Prospectively collected data from 
356 patients that underwent open surgical or endovascular repair of a ruptured intracranial 
aneurysm at the Neurosurgical Centre Nijmegen from 2006 to 2012 by two dual trained 
neurosurgeons were retrospectively analyzed. Complication rates, occlusion rates, and 
retreatment rates were obtained. Combined procedural persistent neurological morbidity 
and mortality after endovascular treatment and open surgical clippingwere 2.1%and 
1.4%, respectively. Overall procedure-related clinical complication rate for endovascular 
treatment was 5.9% in 285 procedures for 295 aneurysms. Overall procedure-related 
clinical complication rate for open treatment was 9.9% in 71 procedures for 72 aneurysms. 
Follow-up was available for 255 out of 295 coiled aneurysms, 48 aneurysms recurred and 
34 needed retreatment. For clipping 54 out of 72 treated aneurysms had follow-up; four 
aneurysms were incompletely clipped. One aneurysm was retreated. Treatment of ruptured 
intracranial aneurysms by neurosurgeons that perform both open surgical clipping as well as 
endovascular techniques is safe and effective. Developing training programs in Europe for 
hybrid neurosurgeons that can provide comprehensive patient care should be considered.
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IntroductIon
background
In many countries neurosurgeons have both open surgical as well as endovascular techniques 
in their armamentarium to treat patients with subarachnoid hemorrhage. In Europe 
neurosurgeons perform open surgical vascular procedures, however, only very few of them 
are trained in endovascular treatment. It is often questioned if one physician would be 
able to conduct both open and endovascular techniques successfully and safely. To answer 
that question, we, two neurosurgeons that perform both open neurosurgical clipping and 
endovascular coiling, evaluated our results of 356 patients treated at our centre for ruptured 
intracranial aneurysms. In this report we focus on safety and efficacy of the procedure.
MAterIAls And Methods
Data of all patients that underwent open surgical or endovascular repair of a ruptured 
intracranial aneurysm at the Neurosurgical Centre Nijmegen (Radboud University Nijmegen 
Medical Centre and Canisius Wilhelmina Hospital Nijmegen) from 2006 to 2012 by two 
neurosurgeons (HDB & JDV) were prospectively entered in a database by a dedicated 
physician’s assistant. Complications were registered by the same physician’s assistant. 
Complications were cross-checked using the neurosurgery department complications 
registry.
Complications were recorded as being radiological / intraprocedural with no clinical 
neurological consequences, complications with transient neurological deficit, and with 
permanent neurological morbidity or dead. Also non-neurological procedural complications 
were registered. Complications were analyzed as of a primary treatment modality and on 
a per patient basis.
Recurrence rates and retreatment rates were analyzed as well.
decision-making process
The majority of patients were coiled. The reasons not to treat a patient with coiling were 
the following: middle cerebral artery aneurysmswith a space-occupying hematoma; 
aneurysms that both had an unfavorable dome-to-neck ratio for coiling and that were 
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expected to be amenable for clipping as well; and patients with vascular anatomy unfavorable 
for endovascular navigaton (for example severe tortuosity of proximal vessels, carotid 
stenosis).
training
The senior author (JDV) had his open surgical and the first part of his endovascular training 
at the Department of Neurosurgery, University of Freiburg, Freiburg, Germany. His further 
endovascular training was done at the Department of Radiology, Radboud University 
Medical Centre Nijmegen, Nijmegen, Netherlands and the last part at the Department of 
Neuroradiology, Karolinska Institute, Stockholm, Sweden. The other author (HDB) had 
his open surgical and endovascular fellowship at the Radboud University Medical Centre 
Nijmegen, Nijmegen, Netherlands. For theoretical sub specialization both attended and 
successfully completed the Master in NeuroVascular Diseases (Université Paris Sud-Faculté 
de Médecine de Bicêtre & Mahidol University, Ramathibodi and Siriraj Medical Schools), 
and the Pierre Lasjaunias European Course of Diagnostic and Interventional Neuroradiology 
(ECNR-course).
results
Included studies
From July 28th 2006 to January 1th 2013, all patients with aneurysmal subarachnoid 
hemorrhage (SAH) were prospectively entered in a database by a physician’s assistant. 
Threehundred-fifty-six patients with 367 aneurysms were treated, 239 (67.1%) were female, 
117 (32.9%) male. Nine moribund patients were not treated and died shortly after admission. 
Mean age was 54.6 years (Table 5.1). Clinical presentation as reported by a Hunt & Hess 
grade is given in Table 5.1. Seventy-one patients with 72 aneurysms were treated by surgical 
clipping (one patient had two aneurysms treated in the same procedure), 285 patients with 
295 aneurysms were treated endovascular (285 coiling procedures). In 11 patients with 
two aneurysms, treatment was done for both aneurysms if either could be the cause of the 
SAH. Open surgical treatment was most frequently done for middle cerebral artery (MCA) 
aneurysms. Anterior communication aneurysms were most frequent in the endovascular 
treatment group, for detailed information see Table 5.2.
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Table 5.1 Demographic data SAH patients
Open (%) Endovascular (%) Overall
Number of patients 71 (19.9) 285 (80.1) 356 (100.0)
Male 18 (25.4) 99 (34.7) 117 (32.9)
Female 53 (74.6) 186 (65.3) 239 (67.1)
Number of aneurysms 72 (19.6) 295 (80.4) 367 (100.0)
Age, mean [SD] 53.1 [10.7] 55.0 [13.2] 54.6 [12.8]
Hunt & Hess
1 12 (16.9) 44 (15.4) 56 (15.7)
2 17 (23.9) 93 (32.6) 110 (30.9)
3 11 (15.5) 61 (21.4) 72 (20.3)
4 18 (25.4) 50 (17.5) 68 (20.2)
5 13 (18.3) 37 (13.0) 50 (14.0)
Table 5.2 Aneurysm location
Aneurysm location
Open; 
number of aneurysms n, (%)*
Endovascular; 
number of aneurysms n, (%)*
Anterior circulation 62 (86.1) 186 (63.0)
Internal carotid 2 (2.8) 4 (1.4)
Ophthalmic - 3 (1.0)
Paraophthalmic - 7 (2.4)
Anterior choroidal - 3 (1.0)
Carotid terminus 1 (1.4) 7 (2.4)
Anterior communicating 12 (16.7) 132 (44.7)
A1 or A2 - 3 (1.0)
Pericallosa - 7 (2.4)
Middle cerebral 47 (65.3) 20 (6.8)
Posteroir circulation 10 (13.9) 109 (36.9)
Vertebral - 6 (2.0)¶
Posterior inferior cerebellar - 10 (3.4)
Superior cerebellar 1 (1.4) 8 (2.7)
Basilar terminus - 28 (10.6)
Posterior cerebral - 3 (1.0)
Posterior communicating 9 (12.5) 52 (17.6)
Mid-basilar - 2 (0.7)
Total 72 (100) 295 (100)
¶ In 4 patients parent vessel occlusion because of a dissecting aneurysm. 
* Data in parentheses are percentages of aneurysms of total within each group (open or endovascular).
In five patients the intended endovascular coiling was converted into open surgical clipping 
as the aneurysms in these patients appeared to have a very wide-neck and could not be 
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treated by endovascular means even with the use of a balloon or double catheter technique. 
Stent-assisted coiling was considered to be the most appropriate treatment modality in 
11 patients.
complications
Endovascular treatment of ruptured aneurysms was associated with 2.8% neurological 
morbidity and 1.1% mortality in our series. Neurological morbidity was transient in 1.8%, 
permanent in 1.1% and non-neurological complication occurred in 2.1% of the cases.
Overall procedure-related clinical complication rate for endovascular treatment was 5.9% in 
285 procedures for 295 aneurysms. Radiological complications without clinical consequences 
were present in 7.7%. Coil perforation was present in 1.4% of the cases and remained without 
clinical sequelae. Combined procedural persistent neurological morbidity and mortality 
after endovascular treatment was 2.1% (Table 5.3).
Open surgical clipping (71 procedures) was associated with 8.4% neurological complications. 
There was no surgery related mortality. Neurological deficit was transient in 7.0% and 
Table 5.3 Complications in endovascular procedures
Complications
Radiological 
without clinical 
consequences 
n, (%)
Transient 
complications
n, (%)
Permanent 
complications
n, (%)
Mortality
n, (%)
Non-
neurological
n, (%)
Aneurysm perforation 4 (1.4) 0 0 0 0
Coil protrusion 3 (1.1) 0 0 0 0
Vasospasm 4 (1.4) 0 0 0 0
Thromboembolism 4 (1.4) 5 (1.8) 3 (1.1) 3 (1.1) 0
Dissection 1 (0.4) 0 0 0 0
Acces not possible 
via groin next day via 
brachial artery
1 (0.4) 0 0 0 0
Anerysm spurium 0 0 0 0 4 (1.4)
Retroperitoneal 
hemorrhage
0 0 0 0 1 (0.4)
Myocardial infarction 0 0 0 0 1 (0.4)
Attempted coiling not 
possible: clipping
5 (1.8) 0 0 0 0
Total 22 (7.7) 5 (1.8) 3 (1.1) 3 (1.1) 6(2.1)
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permanent in 1.4% of the cases. Non-neurological complications were present in 1.4%, 
not including meningitis. Meningitis was diagnosed in all cases with external drainage and 
considered to be related to the external drainage rather than the operation per se. Overall 
procedure-related clinical complication rate for open treatment was 9.9%. There were no 
patients with new postoperative seizures.
Combined procedural persistent neurological morbidity and mortality after open surgical 
clipping was 1.4% (Table 5.4).
Table 5.4 Complications in open surgical procedures
Complications
Procedural, 
without clinical 
consequences 
n, (%)
Transient 
complications
n, (%)
Permanent 
complications
n, (%)
Mortality
n, (%)
Non-
neurological
n, (%)
Intra operative 
aneurysm rupture 
3 (4.2) 0 0 0 0
Hypodensity / 
infarction
2 (2.8) 0 0 0 0
Epidural / subdural 
hematoma
0 2 (2.8) 0 0 0
Neurological deficit NA 3 (4.2) 1 (1.4) 0 NA
Skull fracture 0 0 0 0 1 (1.4)
Additional coiling 
needed
2 (2.8) 0 0 0 0
Total 5 (7.0) 5 (7.0) 1 (1.4) 0 1 (1.4)
NA = not applicable.
recurrence and retreatment
There were 255 out of 295 aneurysms that had follow-up imaging, 48 (18.8%) had a 
recurrence, of these 34 (13.3%) required retreatment with a mean follow-up of 13.8 months 
(range: fu at discharge – 83 months).
Fifty-four out of 72 clipped aneurysms had follow-up imaging. Four (7.4%) neck rests were 
found, one aneurysm was retreated (1.9%) with a mean follow-up of 6.5 months (range: fu 
at discharge – 56 months).
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dIscussIon
This series demonstrate that treatment of patients with ruptured aneurysms by neurosurgeons 
that perform both clipping and coiling is safe and effective.
endovascular treatment
In the present series overall procedural neurological permanent morbidity and mortality 
rates for endovascular procedures were 1.1% and 1.1%, respectively. Transient neurological 
deficit was present in 1.8%. Compared to data in the literature, our complication rates are 
low. Permanent complications are present in 2.4% according to a large study of Brilstra 
reviewing 509 aneurysms in 14 studies.3 In other case series the rate for procedural permanent 
morbidity ranges from 3.2% to 5.9%.7,10,15,27 Transient morbidity ranges from 0.8% to 3.4%.10,15 
Mortality in the aforementioned review was 1.1%.3 Indivudual case series had somewhat 
higher rates ranging from 1.5% to even 7.5%.7,10,15,27 Reported rate of perforation in the review 
of Brilstra was 2.8%.3 Cloft reported on perforations in their meta-analysis of 12 studies 
in 1,248 SAH patients in 4.1%.6 Other case series had rates from aneurysm perforation in 
2.5% to 7.6%.7,10,15,22,27 Rupture due to perforations can be without clinical consequences 
in 73–83%.4,20,27 Thromboembolism is the main cause of morbidity and mortality in our 
series, accounting for totally 2.2% of combined morbidity and mortality. In 15 patients 
thromboembolic (TE) complications were encountered, in four of these patients only small 
thrombus formation was noted and remained clinically silent. Ross reported clinically 
significant thromboembolism in 6% of the case series with 70% ruptured aneurysms. Dinc 
in his series of 481 SAH patients reported 5.0% TE complications with clinical sequelae. Van 
Rooij et al., reported TE events to account for 4.7% of combined morbidity and mortality. 
Inability to treat the aneurysm endovascular accounts probably for 4–37% of the cases.13,14,28 
In conclusion, concerning endovascular treatment of ruptured intracranial aneurysms, 
the results of present series are in the lower range of complication rates reported in 
the literature.
In this series recurrence rate after coiling was 18.8%. Retreatment rate was 13.3%. A recent 
systematic review of 8,040 aneurysms showed a recurrence rate after coiling of 20.8% and 
retreatment rate of 10.3%.8 Our results are in line with this systematic review.
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open surgical treatment
In open surgical treatment procedure-related permanent neurological morbidity was present 
in 1.4%. There was no surgery related mortality. In SAH it might be difficult to discern 
between disease and procedure related adverse events, also in patients with very bad clinical 
condition additional neurological deficit might be difficult to notice. In the context of these 
restrictions results should be interpreted. Mortality from unruptured aneurysm series ranges 
from 1% to 3%.28 Wong et al., performed a review of complications related to open surgery 
for which the main preoperative complications can be listed; intraoperative rupture 19–35%, 
major vessel occlusion 3–12%, medical adverse events 2–17%, seizures 4–42% failure to 
secure rupture site 1–6%.28 In a recent study data fromthe Intraoperative Hypothermia 
for Aneurysm Surgery Trial (IHAST) were analyzed for occurrence of a postoperative 
neurological deterioration.12 Acute postoperative neurological deterioration was observed in 
42.6%. Compared to the abovementioned data the procedure-related persistent neurological 
morbidity and mortality after surgical clipping in our series are low. The open surgical group 
had a higher overall procedure-related clinical complication rate than the endovascular 
group (9.9% vs 5.9%). Although the present series is not a randomized study, our results 
could reflect to the more invasiveness of open surgery. This was well documented in 
randomized studies, although these studies focused on six month and one year follow-
up.13,14 Interestingly the Barrow Ruptured Aneurysm Trial showed similar outcomes based 
on mRS score between coiled and clipped aneurysms of the anterior circulation at three 
year follow-up.25 In this study patients in the clip group had a significantly higher degree 
of aneurysm obliteration and a significantly lower rate of recurrence and retreatment. A 
recent case series in which treatment results of dual trained neurosurgeons were analyzed 
also demonstrated a higher permanent procedure-related neurological morbidity in clipped 
patients than in coiled patients (8.3% versus 3.7%).5 Another case series of a single dual 
trained neurosurgeon disclosed almost equal rates of combined procedure-related persistent 
neurological morbidity and mortality (2.8% for coiled patients and 3.5% for clipped patient).1 
Persistent procedure-related neurological morbidity and mortality after surgical clipping 
and endovascular treatment were similar in our series as well.
In this series incomplete clipping rates were 7.4%. There was one patient who had retreatment 
after clipping. In the literature, rates of incomplete clipping vary between 5% and 30% as was 
demonstrated in a recent meta-analysis.26 Incomplete clipping had occurred in 20% of the 
patients included in the International Subarachnoid Aneurysm Trial (ISAT).14 In conclusion, 
our rates of incomplete clipping are in line with the literature.
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historical background and a changing neurovascular world
Neurosurgery focuses on invasive treatment of neurological diseases. An important part 
of neurosurgical care includes the treatment of neurological emergencies among which 
cerebrovascular diseases form the main group. Patients with ruptured aneurysms will 
stay at neurosurgical wards for several weeks. Thus, both neurosurgeons as well as their 
neurosurgical residents have build up extensive knowledge in treating patients with 
cerebrovascular disease. So typically neurosurgeons have been responsible for comprehensive 
care of patients harboring aneuryms.
Today the neurovascular realm has changed and the vast majority of patients with ruptured 
aneurysms is being treated with endovascular techniques. In our series 80% of the patients 
were coiled. In the vast majority of European centres coilings are performed by radiologists. 
This means that the extensive knowledge which is available in the neurosurgical community 
is not being transferred into an invasive therapy performed by a neurosurgeon. This is an 
interesting contradiction as the core task of neurosurgery is treating neurological diseases 
by invasive techniques.
There are numerous reports on training neurosurgical residents in endovascular neurosurgery 
and outside Europe the realm of endovascular treatment has been entered by many 
neurosurgeons.9,11,16,18,21 In these reports it is concluded that there is a benefit in extending 
the armamentarium of the neurosurgeon with endovascular techniques. Neurosurgeons that 
perform diagnostic and therapeutic angiography increase their knowledge of neurovascular 
anatomy.21 The experience and knowledge obtained in one technique (endovascular or 
open) is useful for the other. By performing both open as well as endovascular techniques 
there is an unbiased and well-considered assessment of which therapy would be indicated 
in a given patient.21 A recent study showed good treatment results of a single dual trained 
neurosurgeon with low complication rates for both coiled and clipped patients (respectively 
2.8% and 3.8%).1 The results of our series suggest as well that dual trained neurosurgeons 
can perform both coiling and clipping with very low complication rates.
The hybrid neurosurgeon can carefully weigh the benefits of either treatment modality and, 
therefore, is able to offer a comprehensive patient care. There are many factors that have to 
be weighed in order to choose between open or endovascular therapy. Clinical factors that 
have an impact on choice of treatment modality are clinical grade, age, and comorbidity 
(cardiac/pulmonary, hematological, or kidney disease, and contrast allergy). Radiological 
factors are: presence of a spaceoccupying hematoma and brain edema. Angiographic 
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factors are: aneurysm location, aneurysm architecture, and condition of proximal arteries 
(starting with the femoral artery up to the parent artery from which the aneurysm arises) 
that need to be catheterized. This gives the hybrid neurosurgeon the possibility to evaluate 
each aneurysm on a case-by-case basis.1 Decision-making can be refined. For example: the 
dogma that “MCA aneurysms should be clipped” can be modified as small MCA aneurysms 
with a favorable dome-to-neck ratio are good candidates for coiling. This paper has not 
proven that a hybrid neurosurgeon has better results than a collegial team. This could only 
be proven in randomized trials. But the question is: are such trials needed? We feel that are 
several ways to offer optimal comprehensive patient care at a given institution.
It may be discussed that a hybrid neurosurgeon will have a preference for one of the both 
techniques. This might influence his/her decision whether to clip or to coil. The question 
is: does that matter as long as his/her results are good?
During our endovascular training program, there was a high enough case-load to be trained 
in special endovascular techniques like balloon-remodeling and stent-assisted coiling. For 
open neurovascular training the range of clipping techniques as well as skull base approaches 
could be trained. As indications for bypass surgery had dramatically dropped over the last 
years, training for this type of surgerywas not included in the open surgical program. We 
have started to cooperate with a high-volume-bypass neurosurgical centre as both authors 
of the manuscript do not perform bypass surgery.
If the number of clippings will further decrease, the aforementioned positive interaction 
of the two techniques might become more and more important. If clippings become rare, 
neurosurgeons that perform open techniques should be as much as possible involved 
in treating cerebrovascular diseases. Today, most European centres still have senior 
neurosurgeons that were trained in the years that most patients were clipped. For younger 
neurosurgeons it will take many years to finish a proper training because of the decreasing 
case-load. There are several ways to solve this issue, like further centralization of this low-
volume, high-complex disease. Neurosurgeons performing both techniques, however, might 
be a more appropriate solution. Apart from the positive interaction between both techniques 
there are relevant patient-care logistic issues to mention. By having divided the invasive 
treatment of patients with ruptured aneurysms between two specialties (neuroradiology 
and neurosurgery), there is need for a double 24/7 emergency service,which makes this 
service more complex and more expensive. Apart from complexity and costs, the efficiency 
of a neurosurgeon being on call just for clipping is very low considering the frequency in 
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which a clipping is necessary. This might discourage young neurosurgeons to sub-specialize 
in open cerebrovascular treatment only. 
An alternative for a dual trained neurosurgeon would be to train neuroradiologists in both 
open and endovascular techniques. Such training programs have not yet been developed.
endovascular training in europe
Recently the European Society of Neuroradiology (ESNR), the European Board of 
Neuroradiology (EBNR), the European Union of Medical Specialists (UEMS) Section of 
Neurosurgery, and the European Association of Neurological Surgeons (EANS) approved 
guidelines for Standards of training in endovascular neurointerventional therapy.18 Thanks 
to this regulation we were able to start an endovascular fellowship program in our centre. 
In Europe still there are only few neurosurgeons trained in endovascular techniques and 
training programs are mostly dependent on local initiatives. Hybrid neurosurgeons are 
even rarer. 
This while neurosurgeons contributed significantly to the initiation of neuroendovascular 
techniques.17 In the last two decades, however, interventional neuroradiologists were the most 
active in this field. Therefore, neurosurgeons entering the endovascular field should work 
in close collaboration with interventional neuroradiologists, creating a positive interaction 
between the both groups. Neurologists as well have shown great interest in this field, and 
it is expected that the lines between neurology, neurosurgery, and radiology will blur.24
Outside Europe, numerous hybrid training programs for neurosurgeons have been developed.
Typically these programs incorporate the endovascular training into the neurosurgical 
residency.24 A recent study could document the safety and efficacy of training a senior 
neurosurgical resident in diagnostic transfemoral catheter angiography.23 
A recently published document mentions the aimto acquire “particular qualification” in 
“interventional neuroradiology” (INR).19 Like Non-European Neurosurgeons, we feel it 
would be very effective for European Neurosurgeons as well to have the opportunity to 
perform the clinical neurosciences as well as the diagnostic neuroradiology part during 
their neurosurgical residency.
From the perspective of INR, European training standards are very well defined. In these 
documents, however, only the endovascular treatment part is considered. For optimizing 
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patient care a comprehensive approach is warranted. We feel that there is an essential and 
urgent task for the European neurosurgical community to take up the responsibility to 
develop European training standards, and to organize and support training programs for 
both open vascular neurosurgery, and hybrid vascular neurosurgery in order to guarantee 
a comprehensive neurovascular patient care.
In a recent comment it was pointed out that even current training standards are incomplete.2 
In this commentary it was stated that current programs do not provide basic sciences 
needed for endovascular surgery, such as vascular biology, vascular physiology expertise 
in the coagulation cascade, and study of the endothelium. Updating of training programs 
is essential.
This series shows that both the endovascular and the open training program were safe as 
complications of both clipping and coiling were low. Thus, the standards of training as approved 
by the abovementioned societies have worked for our centre. There were no differences 
in complication rate between the senior and the junior author. Thus, under controlled 
supervising, patients do not suffer from the learning curve of the trainee. We feel there is 
no essential difference between training an open neurosurgical or endovascular procedure. 
From the early beginning of their residency, neurosurgical residents typically are trained in 
numerous percutaneous surgical procedures. The specific eye-hand-coordination needed 
for those procedures resembles very much the coordination that is needed for endovascular 
procedures. As the number of clippings is significantly lower than the number of coilings it 
will take much longer for a cerebrovascular neurosurgeon to develop skills in clipping.
conclusIons
This series demonstrate that neurosurgeons that perform both endovascular and open 
treatment for ruptured cerebral aneurysms can do this with low morbidity and mortality 
and high efficacy. We encourage other European neurosurgeons to start up endovascular 
treatment together with interventional neuroradiology. Current European regulations for 
training provide a framework to develop this subspecialty of endovascular neurosurgery. 
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AbstrAct
Background Aneurysmal subarachnoid hemorrhage (aSAH) is a condition affecting 
relatively young patients and has high rates of morbidity and mortality. Online health 
communities have emerged to fill the void for patient advocacy and information, allowing 
individuals with shared experiences and chronic disorders to connect.
Objective We have developed an online health community for aSAH patients, and this 
pilot study was conducted to evaluate it from a patient’s perspective.
Methods We implemented an online, members-only, health community (MijnSAB, 
translation: MySAH) in addition to the usual aSAH care at Radboudumc, Nijmegen, the 
Netherlands. A questionnaire that was sent to consecutive aSAH patients was used to evaluate 
the usability and utility of MySAH. Answers were provided using a 5-point Likert scale. There 
was also one open-ended question asking about what was missing from the MySAH tool.
Results In total, 66 consecutive patients with aneurysmal subarachnoid hemorrhage were 
informed about the online health community. Of 64 potential MySAH users, 26 patients 
gained access to MySAH, 20 of whom were willing to participate in the evaluation. Those 
who used the community were younger (p = 0.03) and in a better condition at discharge 
(p = 0.03). The patients were positive about MySAH’s contribution to the quality of their 
care, but not to their quality of life. Most patients (18/20, 90%) reported that they would 
recommend the community to others in their position. Open suggestions on how to improve 
the tool included more frequent blogs, including by a rehabilitation specialist. 
Conclusions This pilot study showed that the online health community, MySAH, has 
a beneficial effect on the aftercare of patients suffering from aSAH because it gives easy 
access to relevant information provided by peers or caregivers. Due to the variable clinical 
outcomes after aSAH, the tool will mainly be useful for a select group of patients (with a 
better clinical outcome).
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IntroductIon
The incidence of aneurysmal subarachnoid hemorrhage (aSAH) is approximately nine 
cases per 100,000.5 The condition affects relatively young patients, with an average age at 
first onset of 55 years, and has significant rates of morbidity and mortality.5 Health-related 
quality of life is also significantly reduced compared to the normal population.8,9,11 Online 
health communities are increasingly being used to assist these patients and can be a valuable 
addition to the standard clinical and outpatient care.1,12,18 Such communities give patients 
the opportunity to communicate with professionals and peers and to learn more about their 
disease and future expectations.10
We have developed an online health community for aSAH-patients, and this pilot study was 
conducted to evaluate it from a patient’s perspective.
methods
Implementation
We implemented an online, members-only health community (MijnSAB, translation: 
MySAH) as an addition to the usual aSAH care provided at Radboudumc. The tool has three 
main functionalities, which are in line with those described for other online communities.1 
First, information on relevant news can be provided in blogs. Second, the resource is an 
interactive forum whereby patients can contact others with the disease or put questions to 
the medical team. Third, general information concerning several aspects of the disease is 
provided. An example of the access page in the form of a poster used for promotion purposes 
among patients is shown in Figure 6.1. Examples of the translated content (“Can I?”) are set 
out in Multimedia Appendix 6.1.
The community tool has been used by Radboudumc to improve patient-centered care in a 
number of different medical specialties, with ParkinsonNet being an example.18 The technical 
maintenance costs are € 5000 per annum. 
In our MySAH community, patients logged in to the site using a personal digital identification 
code. Attention was drawn to new messages by pop-ups in a patient’s mailbox. Two physician 
assistants and a nurse practitioner were responsible for daily communication with the 
community. Weekly checks on the Web-blogs were made by two neurosurgeons. General 
questions without the need for the intervention of a neurosurgeon were answered by the 
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physician assistants or nurse practitioner. If the answers to questions required more specialist 
knowledge, responses were provided by one of the two neurosurgeons. 
We used a questionnaire, which was sent to consecutive aSAH patients, to evaluate the 
usability and utility of MySAH. If patients were unable to complete the questionnaire, their 
caregivers were asked to do it for them. Those who did not return a completed questionnaire 
within 3 weeks were contacted by telephone and asked why. An eventual telephone evaluation 
was conducted by a physician assistant who was not involved in the treatment of the patients.
All of the aSAH patients referred to Radboudumc between November 1, 2012, and September 
30, 2013, were candidates for participation, and all survivors were invited to take part in 
the research. The demographics of all of the referred patients were registered, as were 
the modified Rankin scale (mRS) at discharge and the type of post-hospital care (home, 
Figure 6.1 Poster of access page.
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rehabilitation, or nursing home). The mRS is frequently used in aSAH patients to score 
outcomes and is an ordinal scale varying from 0 to 6 (0 = No symptoms; 1 = No significant 
disability. Able to carry out all usual activities, despite some symptoms; 2 = Slight disability. 
Able to look after own affairs without assistance but unable to carry out all previous activities; 
3 = Moderate disability. Requires some help but able to walk unassisted; 4 = Moderately 
severe disability. Unable to attend to own bodily needs without assistance and unable to walk 
unassisted; 5 = Severe disability. Requires constant nursing care and attention, bedridden, 
and incontinent; and 6 = Dead). The mRS scores have been dichotomized as ≤ 3 and ≥ 4 
because it was assumed that patients with a score of more than 3 would use the Internet 
less often. Approval for the study was obtained from the local medical ethics committee 
(CMO Arnhem-Nijmegen).
Questionnaire
We developed a questionnaire that had two parts. The first of these contained general 
questions on perceived care, while the second asked questions on the usability and usefulness 
of the MySAH community. The questions were adapted from a previously published patient 
agreement questionnaire containing usability-related and usefulness-related statements and 
were expanded for use with MySAH.15 Answers were given using a 5-point Likert scale, 
the data were summarized by a median, and for the analysis, the results were collapsed in 
two categories, with the neutral score counted on the negative side (agree/disagree). The 
results are presented graphically with median and interquartile ranges.7 There was one open-
ended question about what was missing from the MySAH tool. If possible, the responses 
were classified according to the three components of the community and with respect to 
suggested technical alterations.
results
Included patients
In total, 66 patients with aneurysmal subarachnoid hemorrhage were informed about 
the online health community. Two patients died in the post-discharge period. Of the 
64 remaining potential MySAH users, 38 did not log in, 4 could not be contacted in the 
post-operative period, 3 were willing to log in after a rehabilitation period, 2 did not log in 
because of their clinical condition, 5 had technical difficulties logging in, 5 did not have a 
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computer, and 19 did not provide a reason for their non-participation. Finally, 26 patients 
did gain access to MySAH, 20 of whom were willing to participate in the study (Figure 6.2). 
The demographics of the patients, stratified by their participation, are shown in Table 6.1.
The participants who evaluated MySAH were not significantly different in terms of their 
gender or discharge location (p = 0.33). However, those who did participate were younger 
(p = 0.03) and were in a better clinical condition (mRS) at discharge (p = 0.03).
Patient satisfaction and the use and usability of mysAh
The MySAH community was used for a mean period of 7.2 months, mainly bi-monthly 
(9/20, 45%) or monthly (7/20, 35%). A minority used the tool weekly (3/20, 15%) or daily 
(1/20, 5%). In most cases (16/20, 80%), the patient was the main user of MySAH, while 
the other responders were proxies. No specific part of the MySAH community was used 
Figure 6.2 Flow chart of patients included in study.
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preferentially by either the patients (wiki: 4/20, 20%; forum: 10/20, 50%; blogs: 2/20, 10%; 
not answered: 2/20, 10%) or their proxies (wiki: 3/20, 15%; forum: 2/20, 10%; blogs: 2/20, 
10%; and not answered: 12/20, 65%).
The questionnaires were mainly completed by the patients and in a minority of cases by their 
caregivers. Patient satisfaction with treatment, post-treatment care, and communication 
with caregivers was generally rated positively (see Figure 6.3).
The information was easy to use (4.0) and find (4.0) and was also clear (5.0). However, it was 
not beneficial for managing health, making important decisions regarding health (2.5), or 
making contact with caregivers (3.0). Patients were positive about MySAH’s contribution to 
the quality of their care, but not to their quality of life. No specific component (blog, forum, 
or wiki) was preferentially rated, nor did the patients discard one aspect in particular. Most 
patients (18/20, 90%) would recommend the community to others in their position.
open remarks
In total, 16 patients made 21 suggestions for future improvements to the community (Table 
6.2). These responses were classified according to the three components of the community 
and with respect to suggested technical alterations. More frequent blogs, including by 
a rehabilitation specialist, was one suggestion. The forum could apparently also benefit 
Table 6.1 Patient characteristics
Participant
Non-
participant Total
P value for calculated 
difference between groupsa 
Number of patients, n (%) 20 (30) 46 (70) 66 (100) Not applicable
Male/female, n/n 6/14 17/29 23/43 0.78b
Age in years, median (SD) 48.5 (11.7) 56.0 (11.9) 54.0 (12.2) 0.03c
mRS at discharge, n
≤ 3 19 31 50 0.03b
≥ 4 1 15 16
Discharge, n
Home 14 22 36 0.33b
Rehabilitation 5 18 23
Nursing home 1 6 7
a Values are considered to be significant if p < 0.05.
b Fisher’s Exact test (2-sided).
c Mann-Whitney U test (2-tailed).
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from use by a larger number of patients overall and by patients with more positive disease 
experiences. The wiki section should contain more information about aftercare, psychological 
consequences when at home, pregnancy after aSAH, current news, and more general factors. 
Other suggestions were related to login and layout and navigation on the site.
dIscussIon
Principal findings
The conceptual framework of the online community, MySAH, is to improve patient care 
and obtain better clinical outcomes through optimizing engagement of the patient with the 
treatment. This is accomplished by an exchange of information between patient and caregiver 
and vice versa. Such a concept is comparable with sociological studies in other fields.17
This online health community has promising features. Although the number of responses to 
the questionnaire was not high (30% responders), the majority graded the items concerning 
usability as good. The response rate is probably related to the clinical outcome after aSAH; the 
patients using the community were generally in better health, which means that it may not 
be valuable for those in a worse condition. The users of the community were also younger, 
which is generally the case with health-related Internet use.19
At our center, the treatment of aSAH patients is carried out by a subspecialist team 
working in a multidisciplinary setting. This team consists of neurologists, neurosurgeons, 
neuroradiologists, neurorehabiliation specialists, neurointensivists, and a dedicated nursing 
team using a protocolized aftercare program. This probably contributes to patient satisfaction 
with treatment, post-treatment care, and communication with caregivers. As important 
decisions are already taken within this framework, it is likely that no additional benefit of the 
Table 6.2 Items for improvementa
Item Suggestion
Blogs More blogs (1), in combination with rehabilitation specialist (2)
Forum More patient contact (1), also positive experiences (1)
Wiki / information More information on aftercare (2), psychological consequences at home (3), 
pregnancy after aSAH (1), current news (2), and general information (3)
Technical Login (1), navigation (1),  layout (3)
a Numbers in parentheses = number of patients who suggested this improvement.
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online health community was identified with respect to managing health, making decisions 
regarding health, or making contact with caregivers. Moreover, a recent study investigating 
the use of an online forum identified a participant’s motivation to seek out information as 
one of the factors related to participation in an online community.4
However, the patients were positive about MySAH’s contribution to their quality of 
care. Indeed, with the increasing centralization of subspecialized care, this online health 
community can provide additional, easy access (after-) care at a distance without the need to 
travel.3 This was also emphasized in the open suggestions made by the patients concerning 
how to improve communication with the specialists (rehabilitation specialist) involved with 
health care after aSAH, and could be valuable in a future online health community. Such a tool 
would enable answers to be provided quickly on apparently less important, but for the patient 
at their stage of rehabilitation, very relevant issues (eg, washing hair, biking, sex). MySAH 
might also serve as a tool for self-management whereby patients are helped to gain control 
over their lives.18 Additionally by implementing and evaluating this online community, 
patient engagement has led to advancements in the aftercare, especially by improved and 
tailored information. A lesson learned: for future caregivers starting a community, careful 
selection of the possible participants and their needs is paramount.
As indicated in other publications, household Internet access in the Netherlands is about 
92% and should therefore be a minor limitation with respect to access to an online health 
tool.16,18 Indeed, this is in line with our data in which only five of 66 patients (7.6%) did not 
have a computer. However, in some other states in the European Union, Internet access 
is less, down to 45%, and might therefore be a restricting factor in the success of such an 
online community.16,18 
Health-related quality of life is significantly reduced in patients with aneurysmal sub-
arachnoid hemorrhage.6,8,9 Important factors associated with this are physical health issues, 
depression, cognitive impairment, anxiety, and fatigue,2,8,9,13,20 and standard aftercare and 
rehabilitation focuses on these problems. These impairments may, however, have been 
barriers to the use of the community by those who might potentially benefit from it. Those 
who did participate evaluated the tool neutrally, regarding their quality of life as neutral.
limitations
This research has several limitations. First, the number of patients evaluated was only 20, 
as some of those approached were unwilling or unable to use the MySAH tool. However, 
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within this pilot study, this outcome highlighted the limitations of the community in this 
patient category. Moreover, for evaluation purposes, having 20 participants is considered to 
be adequate.15 Second, usability was self-reported, although from a quality of life perspective 
the use of subjective experiences is important.20 Third, the online health community was 
used as an additional aftercare program and might have experienced some redundancy.
Future studies should assess the value of this online health community when fully integrated 
in, and as an adjunct to, face-to-face interactions. This could tailor aftercare to the wishes 
of the patient, enabling more patient-centered care. In our view, it should be emphasized 
that face-to-face contact continues to be essential in order to precisely determine outcomes 
and identify possible neurological deficits. Moreover, we envisage a broader use for the 
MySAH community in other centers involved in aSAH care in the Netherlands. Certainly, 
the general sections of the site could productively be used by patients from other centers, 
and the experiences of other caregivers would probably also be beneficial. Furthermore, a 
larger group of active members may possibly facilitate community sustainability.14,21 Indeed, 
organizational commitment and financial and human resources are essential to maintain a 
community, and these efforts can be supported by the involvement of a larger group of people 
who provide care to aSAH patients.21 As a result of the responses to the open questionnaire 
used in this pilot study, information will be added to the wiki section and rehabilitation 
specialists will become engaged in the MySAH community. 
conclusIons
In this pilot study, the online health community MySAH contributed to the aftercare of 
patients suffering from aSAH. There was easy access to information that was relevant 
for patients and families, which could be obtained from peers or caregivers. The MySAH 
community will, however, mainly be useful for a select group of patients because of differences 
in clinical outcomes. 
Acknowledgment
HD Boogaarts received a grant from FondsNuts Ohra (FNO 1204-069) for this research. 
We would like to thank MV Amerongen, MD, for help with the preparation of Figure 6.2. 
Chapter 6
90
references 
1.  Aarts JW, Faber MJ, den Boogert AG, Cohlen BJ, van der Linden PJ, Kremer JA, et al: Barriers and facilitators 
for the implementation of an online clinical health community in addition to usual fertility care: a cross-
sectional study. J Med Internet Res 15:e163, 2013
2.  Al-Khindi T, Macdonald RL, Schweizer TA: Cognitive and functional outcome after aneurysmal 
subarachnoid hemorrhage. Stroke 41:e519–e536, 2010
3.  Bardach NS, Olson SJ, Elkins JS, Smith WS, Lawton MT, Johnston SC: Regionalization of treatment for 
subarachnoid hemorrhage: a cost-utility analysis. Circulation 109:2207–2212, 2004
4.  Das A, Faxvaag A: What influences patient participation in an online forum for weight loss surgery? A 
qualitative case study. Interact J Med Res 3:e4, 2014
5.  de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ: Incidence of subarachnoid haemorrhage: a 
systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry 
78:1365–1372, 2007
6.  Hedlund M, Ronne-Engström E, Carlsson M, Ekselius L: Coping strategies, health-related quality of life 
and psychiatric history in patients with aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien) 
152:1375–1382, 2010
7.  Heiberger RM, Robbins NB: J Stat Soft 5:1–32. 2014 Mar 57. Design of diverging stacked bar charts for 
Likert scales and other applications URL: http://www.jstatsoft.org/v57/i05/paper [accessed 2014-10-28] 
[WebCite Cache ID 6TeznEfwY]
8.  Katati MJ, Santiago-Ramajo S, Pérez-García M, Meersmans-Sánchez Jofré M, Vilar-Lopez R, Coín-Mejias Ma, 
et al: Description of quality of life and its predictors in patients with aneurysmal subarachnoid hemorrhage. 
Cerebrovasc Dis 24:66–73, 2007
9.  Meyer B, Ringel F, Winter Y, Spottke A, Gharevi N, Dams J, et al: Health-related quality of life in patients 
with subarachnoid haemorrhage. Cerebrovasc Dis 30:423–431, 2010
10.  Munson SA, Cavusoglu H, Frisch L, Fels S: Sociotechnical challenges and progress in using social media 
for health. J Med Internet Res 15:e226, 2013
11.  Passier PE, Visser-Meily JM, Rinkel GJ, Lindeman E, Post MW: Determinants of health-related quality of 
life after aneurysmal subarachnoid hemorrhage: a systematic review. Qual Life Res 22:1027–1043, 2013 
12.  Powell JA, Darvell M, Gray JA: The doctor, the patient and the world-wide web: how the internet is changing 
healthcare. J R Soc Med 96:74–76, 2003
13.  Powell J, Kitchen N, Heslin J, Greenwood R: Psychosocial outcomes at 18 months after good neurological 
recovery from aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 75:1119–1124, 
2004
14.  Resnick PJ, Janney AW, Buis LR, Richardson CR: Adding an online community to an internet-mediated 
walking program. Part 2: strategies for encouraging community participation. J Med Internet Res 12:e72, 
2010 
91
Online aSAH health community
15.  Segall N, Saville JG, L’Engle P, Carlson B, Wright MC, Schulman K, et al: Usability evaluation of a personal 
health record. AMIA Annu Symp Proc 2011:1233–1242, 2011
16.  Seybert H. Eurostat Statistics in Focus. European Commission - Internet use in households and by individuals 
in 2011 URL: http://epp.eurostat.ec.europa.eu/statistics_explained/index.php/Internet_use_statistics_-_
individualsArchived [WebCite Cache ID 6RHtY3dSAAccessed20140723]
17.  Valko P, Allen J, Mense C, Worthington S, Sommers J, Brownson R, et al: Community-wide obesity 
prevention: re-connecting public health, urban planning, and public policy in three Missouri communities. 
Community Development 42:152–166, 2011
18.  van der Eijk M, Faber MJ, Aarts JW, Kremer JA, Munneke M, Bloem BR: Using online health communities 
to deliver patient-centered care to people with chronic conditions. J Med Internet Res 15:e115, 2013
19.  van Uden-Kraan CF, Drossaert CH, Taal E, Smit WM, Moens HJ, Siesling S, et al: Health-related Internet 
use by patients with somatic diseases: frequency of use and characteristics of users. Inform Health Soc 
Care 34:18–29, 2009
20.  Visser-Meily JM, Rhebergen ML, Rinkel GJ, van Zandvoort MJ, Post MW: Long-term health-related quality 
of life after aneurysmal subarachnoid hemorrhage: relationship with psychological symptoms and personality 
characteristics. Stroke 40:1526–1529, 2009
21.  Young C: Community management that works: how to build and sustain a thriving online health community. 
J Med Internet Res 15:e119, 2013 
Chapter 6
92
multImedIA APPendIx 6.1 
english translation of frequently asked questions
in category “can I…?” (In dutch; mag ik…?).
“can I…?”
…. fly? Yes you can!
After a subarachnoid hemorrhage, many people wonder if they are allowed to fly. They are 
afraid that the changed air pressure on the plane may cause a new bleed. Medically speaking, 
though, there is no reason not to fly.
…. have sexual intercourse again?
Having sexual intercourse after a subarachnoid hemorrhage… No problem.
After a subarachnoid hemorrhage, many people wonder if they can have sexual intercourse 
again. They are anxious that a new bleed may occur. It is, however, safe to do so and there 
is no increased risk of a new hemorrhage.
It often happens that the physical effects of the hemorrhage (fatigue, headache) or feelings 
of anxiety or apathy affect your relationship and sex life. We recommend that you discuss 
this with your partner. It is also possible to speak about this with one of your healthcare 
professionals.
…. drive my car?
Driving my car after an aneurysm or subarachnoid hemorrhage: is it permitted?
The answer to this question depends on a number of factors. You can read more about 
government regulations in this blog.
If you have a disease or a condition in which fitness to drive is an issue, as a license holder 
you are obliged to report this to the Central Bureau for Driver Licences (Dutch: CBR) by 
way of a “self-declaration”. 
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There are stricter regulations for people who use their license for professional purposes.
The conditions in which this applies are described in the 2000 Ministry of Transport 
and Water regulation: ‘Suitability Requirements’. This regulation was last revised in 2008. 
Subarachnoid hemorrhage and cerebral aneurysms are both discussed in this regulation.
In summary, the following applies:
People with an accidentally-discovered aneurysm that has not bled, and is not being treated, 
are generally considered by the CBR to be appropriate to hold a driving license without any 
time limitations.
People with bleeding from an aneurysm should not drive until six months after the 
hemorrhage. After this period, when fitness to drive is not an issue, a person can be 
considered by the CBR to be suitable to hold a driving license. When there is doubt about 
a dysfunction that may bring the issue of safety into question, the individual’s driving must 
be assessed. In particular, a test drive with an expert from the CBR is required. The CBR 
has a comprehensive protocol for the test drive procedure. When the driving is assessed as 
being good, a license is approved for a term of three years.
If you have any questions about your situation and resuming driving, please discuss these 
with your healthcare professionals.
…. drink alcohol?
A nice glass of wine? You can!
When you are treated for a ruptured aneurysm, you might wonder whether you can drink 
alcohol. There is no harm in doing so, as long as it’s in moderation. Keep in mind the 
medication that you are taking and always read the warnings in the leaflet that comes with 
the drugs.
…. Practice sport?
When you are diagnosed with a subarachnoid hemorrhage due to an aneurysm, you might 
wonder whether you can take part in sport. There is no harm in doing so. In fact, once you’re 
ready, it is good for your health to participate in sports again. 
Please do be aware that you need to build up your physical endurance. However, we 
recommend gradually increasing the duration, intensity and frequency of your exercise. 
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…. Go to the sauna?
It is often asked whether a visit to the sauna is possible after a subarachnoid hemorrhage. 
The answer to this question is ‘Yes’.
A visit to the sauna can be relaxing and is therefore for good for you. Once there, like for 
everyone else, it is important that you drink enough. If you have high blood pressure, it is 
even more important that you adhere to the sauna regulations. In the sauna, your blood 
pressure goes down because the blood vessels expand. When cooling off, the opposite occurs. 
In people with high blood pressure, these fluctuations are greater, meaning that you should 
stick closely to the requirements of the establishment.
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AbstrAct
MR angiography is proposed as a safer and less expensive alternative to the reference 
standard, DSA, in the follow-up of intracranial aneurysms treated with endovascular coil 
occlusion. We performed a systematic review and meta-analysis to evaluate the accuracy 
of TOF-MRA and contrast-enhanced MRA in detecting residual flow in the follow-up of 
coiled intracranial aneurysms. Literature was reviewed through the PubMed, Cochrane, and 
EMBASE data bases. In comparison with DSA, the sensitivity of TOF-MRA was 86% (95% 
CI: 82–89%), with a specificity of 84% (95% CI: 81–88%), for the detection of any recurrent 
flow. For contrast-enhanced MRA, the sensitivity and specificity were 86% (95% CI: 82–89%) 
and 89% (95% CI: 85–92%), respectively. Both TOF-MRA and contrast-enhanced MRA are 
shown to be highly accurate for detection of any recanalization in intracranial aneurysms 
treated with endovascular coil occlusion.
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IntroductIon
The prevalence of unruptured intracranial aneurysms in the world population is approxi-
mately 2–3%.58,71 The current standard treatment to eliminate the risk of (re)bleeding is 
exclusion of the aneurysm from the intracranial circulation by use of endovascular detachable 
coil occlusion.47 However, recurrences occur in approximately 20% of treated patients, leading 
to a need for retreatment in approximately 9% of all cases.49 
DSA is the reference standard for evaluating aneurysms after coiling. However, this technique 
exposes patients to risks such as cerebral thromboembolism, contrast nephrotoxicity, and 
ionizing radiation. The transient neurologic complication rate after DSA has been reported 
to be in the range of 0.34–1.3%, with a risk for permanent neurologic complications of 0.5%. 
This risk accumulates because repeated follow-ups are necessary.15,69,77
MRA can be used for follow-up of coiled intracranial aneurysms, with TOF and contrast-
enhanced (CE) MRA being the most commonly used techniques currently available. MRA 
eliminates the risks of cerebral thromboembolism and ionizing radiation. There is, however, a 
continuing debate about which of these 2 MRA techniques is best suited for aneurysm follow-
up. The systematic review and meta-analysis performed by Kwee et al. in 2007 compared 
TOF-MRA and CE-MRA with DSA for follow-up of coiled aneurysms.41 The analysis 
revealed a moderate to high diagnostic performance of bothMRAtechniques. Because the 
moderate methodologic quality of the studies available at the time, Kwee and Kwee could 
not conclude whether MRA can replace DSA as the standard method of reference.41 Since 
then, the number of studies on this subject has more than doubled, and study setup and 
statistical methodology have substantially improved.
The goal of the current study is to systematically review the medical literature to establish 
whether TOF-MRA and CE-MRA can now be considered good enough for follow-up of 
patients with coiled intracranial aneurysms.
MAtErIALs And MEtHods
data sources
The medical literature comparing MRA and DSA for evaluating intracranial aneurysms 
after coiling was reviewed through the use of a variety of data bases—PubMed, EMBASE, 
and the Cochrane Library—and was updated until March 2012 (Supplemental Table S7.1).
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study selection
After an initial search of the literature by an experienced librarian, duplicate publications 
were removed. From the pooled list of publications, 2 researchers (M.J.v.A. and H.D.B.) 
independently reviewed the titles and abstracts of the articles. Studies were excluded if they 
did not compare MRA with DSA for follow-up of patients with intracranial aneurysms 
treated with endovascular coil occlusion. Conference abstracts, reviews, editorials, meta-
analyses, and animal studies were also excluded. Only articles in English were screened. 
From the remaining articles, full-text versions were obtained and were independently 
evaluated by the same researchers (M.J.v.A. and H.D.B.). Studies were eligible for inclusion 
if they 1) evaluated MRA and DSA for follow-up of patients with intracranial aneurysms 
treated with endovascular coil occlusion; 2) contained data for 22 contingency tables; 3) 
used the Raymond et al. classification or other compatible scales to grade recurrent flow 
in intracranial aneurysms;57,59,60 4) analyzed TOF and CE MRA separately; and 5) provided 
data that excluded stent-assisted coiling of intracranial aneurysms. If the same data were 
used in more than 1 article, the most recent version was included. If the 2 researchers 
disagreed about selection of articles, an independent third reviewer (R.H.M.A.B.) decided 
the outcome.
study quality
The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) 
method was used to assess the methodologic quality of the studies included in this 
review.5,27-35,63 The studies were independently assessed by the 2 researchers (M.J.v.A. and 
H.D.B.) for limitations, indirectness, inconsistency, imprecision, and publication bias. 
Agreement between the researchers was quantified by use of Cohen κ.9 In the case of 
disagreement, a third reviewer (R.H.M.A.B.) made the final decision.
data analysis
The Meta-DiSc software (http://www.hrc.es/investigacion/metadisc_en.htm) and SPSS 
statistical package (version 19.0.0; IBM, Armonk, New York) were used for statistical 
analysis.80 To evaluate effect size, 22 contingency tables were constructed from the articles 
comparing MRA and DSA. If the true-positive rate, false-positive rate, true-negative rate, 
or false-negative rate was zero, a standard correction of 0.5 was added to all of the cells of 
the contingency table. Pooled sensitivity and specificity with 95% confidence intervals were 
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constructed. Data about the accuracy of MRA for grading recurrent flow, as defined by 
Raymond et al.,57,59,60 were extracted if available. Classification scales that were compatible 
with Raymond et al. were also utilized, meaning that the findings could be assigned to 
1 of the following categories: complete occlusion; residual neck (1–3 mm); and residual 
aneurysm (> 3 mm). Results were depicted in a Forest plot and a summary receiver operating 
characteristic (SROC) curve. An SROC curve plots the positive rate against the false-positive 
rate of a diagnostic test at the different possible cutpoints. Heterogeneity between the studies 
was examined by use of the I2 test. As an indicator of low heterogeneity, a percentage < 40% 
was taken.31
rEsuLts
Included studies
Our search string found 424 studies in PubMed, 12 in Cochrane, and 580 articles in 
EMBASE (Supplemental Table S7.1). A total of 681 studies remained after removal of 
duplicates. After screening titles and abstracts, 51 articles were deemed fit for full-text 
evaluation.1,3,4,8,10-14,16-26,36-40,42-46,48,50-56,61,62,64,66,68,70,72-75,78,79,81 No new articles were found by 
screening their references. After evaluation of the full-text versions, 3 articles were excluded 
because they were review papers.40,72,81 Another 5 studies were omitted because they did not 
provide enough data for the 22 contingency tables.1,54,55,61,73 Four further studies were left 
out because they did not compare MRA with DSA,22,53,64,68 while another 4 were not studying 
intracranial aneurysms treated with endovascular coil occlusion.16,36,44,48 Two articles were 
excluded because information about TOF-MRA and CE-MRA could not be separated.17,62 
One article was excluded because it used CE–TOFMRA.8 Another 3 articles were excluded 
because their data were used in earlier studies.13,24,25 Three studies included patients who 
had been treated with a secondary Neuroform stent (Stryker Neurovascular, Fremont, 
California) and were thus omitted (Figure 7.1).11,12,78 This left 26 studies that were eligible 
for inclusion (Figure 7.1; Supplemental Table S7.2).3,4,10,14,18-21,23,26,37-39,42,43,45,46,50-52,56,66,70,74,75,79 
Of these articles, 24 researched TOF-MRA3,4,10,14,18-21,26,37-39,42,43,46,50-52,56,66,70,74,75,79 and 14 
researched CE-MRA.3,14,20,23,38,39,42,43,45,46,50,56,66,75 Twelve studies assessed both TOF-MRA and 
CE-MRA for the detection of recanalization in coiled intracranial aneurysms in the same 
subjects.3,14,20,38,39,42,43,46,50,56,66,75
Chapter 7
102
study quality assessment
We analyzed the methodologic quality of the 26 articles included in our review according 
to the GRADE criteria (Supplemental Table S7.3).5,27-35,63 There was disagreement between 
the assessments by the 2 researchers with respect to 5 of 104 GRADE scores, resulting in a 
Cohen κ of 0.81. All of the articles comprised valid studies comparing MRA with the reference 
standard (DSA). Because of this validity, all of the studies started with a maximal quality score 
of 4.63 None of the articles gave any indication that they contained serious inconsistencies 
or were imprecise.5,27-35,63 Two studies were rated down because of indirectness; they did not 
provide enough information concerning their MRA techniques or only included anterior 
communicating artery aneurysms.37,43 Quality was rated down in 14 studies because of the 
following major limitations: the studies did not include consecutive patients, the studies 
were not prospective, or there was no blinding of the researchers.3,14,19,20,26,39,45,51,52,56,66,74,75,79
Figure 7.1 Search results.
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Pubmed n = 424
Cochrane n = 12
Embase n = 580
Additional records identied
through reference screening
n = 0
Records after duplicates removed
n = 681
Records excluded n = 630
Full-text articles assessed
for eligibility
n = 51
Studies included in
qualitative synthesis
n = 26
Studies included in
quantitative synthesis
n = 26
Articles excluded n = 25
Not enough information for 2x2 table n = 5
No follow-up of coiled aneurysms n = 4
No comparison MRA and DSA n = 4
Review articles n = 3
Data used in later study n = 3
Use of Neurostent n = 3
Information TOF/CE mixed n = 2
Use of CE-TOF MRA n = 1
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data analysis
The pooled results for the sensitivity and specificity of TOF-MRA and CE-MRA are presented 
in Table 7.1. The sensitivity and specificity for the detection of any recanalization, meaning 
residual neck or residual aneurysm, are shown in Figure 7.2A–D. TOF-MRA had both a 
pooled sensitivity and specificity of 86% (95% CI: 83–89%). Pooled sensitivity and specificity 
of CE-MRA were 85% (95% CI: 81–89%) and 88% (95% CI: 84–91%), respectively. SROC 
curves are displayed in Figure 7.3A–B for TOF-MRA and CE-MRA. As shown in Figure 
7.2A–D, the results were subject to heterogeneity, with I2 values ranging between 66–80%. 
For subanalysis, different study variables were distinguished: retrospective versus prospective 
studies, 2D versus 3D DSA, different MR field strengths, GRADE criteria, and weighted 
results according to GRADE (Supplemental Table S7.2).
Figure 7.2 Pooled sensitivity/specificity in detecting any recurrent flow. 
A = Sensitivity for TOF-MRA. B = Specificity for TOF-MRA. C = Sensitivity for CE-MRA. D = Specificity for CE-MRA.
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dIscussIon
The results of our meta-analysis reveal that MRA now has a high degree of sensitivity 
and specificity in detecting any recanalization during the follow-up of coiled intracranial 
aneurysms. However, a subanalysis for residual neck or residual aneurysm (Raymond scale 
Figure 7.3 A, Summary receiver operating characteristic for TOF-MRA. B, Summary receiver operating 
characteristic for CE-MRA.
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2 or 3, respectively) revealed lower sensitivity and specificity of both MRA techniques 
compared with DSA as the reference standard (Table 7.1). A possible explanation is the 
small number of studies and patients included therein, which is reflected in the large 95% 
confidence intervals. Another potential explanation is false-positive findings seen on DSA 
possibly caused by pulsation artifacts.18 However, this comparison makes MRA the reference 
standard compared with DSA. Because our study compared MRA with the reference 
standard, DSA, these cases also were judged in favor of DSA. This results in false-negative 
values for the MRA and a lower sensitivity.
This subanalysis also showed lower sensitivities of the CE-MRA compared with the TOF-
MRA for the detection of residual neck or residual aneurysm. The contrast timing together 
with the narrow interval of scanning in CE-MRA might be the cause of this lower sensitivity. 
The short time window between the arterial and venous phase of contrast enhancement to 
avoid venous enhancement and vessel overlap lowers the spatial resolution.56 Additionally, 
the acquisition time for TOF-MRA is much longer compared with CE images, leading to 
improved resolution. The disadvantage of TOF-MRA is its limited coverage; however, TOF 
is adequate for the evaluation of intracranial vessels. Suboptimal imaging in CE-MRA may 
therefore lead to more false-negative values, especially in small remnants, lowering the 
sensitivity.
Significant sources of heterogeneity in this meta-analysis are variations in study design 
and reporting of data. Evaluation of the studies revealed 5 possible explanations for this 
heterogeneity: 1) Publication bias remains a potential cause of heterogeneity, because articles 
with better results are more likely to be published than studies with insignificant or negative 
findings. 2) Not all of the studies had a prospective design and enrolled patients consecutively, 
which can be a cause of bias.6 Sixteen of the 26 were prospective;4,10,14,19,21,37,39,42,43,46,50,52,56,66,70,75 
only 12 studies included consecutive patients.4,18,21,23,37,38,42,43,46,50,56,70 Retrospective studies 
tended to be better, with low heterogeneity, compared with the results of the prospective 
studies, though these findings were not statistically significant (Table 7.2). 3) For the reference 
standard, 8 reference studies used 3D (rotational) DSA for comparison to MRA,4,23,38,39,45,50,52,79 
whereas the other studies used 2D DSA. Because 3D DSA is better at evaluating recurrent 
flow in intracranial aneurysms,65,67 the use of the 2D DSA may reduce calculated specificity 
but also increase calculated sensitivity of MRA if a true recanalization is missed by DSA. 
The use of DSA as the reference standard will potentially cause DSA false-negative values to 
count as MRA false-positive values. In general, MRA tends to perform better when compared 
with 3D DSA than when compared with 2D DSA (Table 7.2). 4) Heterogeneity may also be 
107
MRA versus DSA
caused by different field strengths used in the various studies.2,7 Five studies only researched 
3T MRA,21,46,50,66,70 whereas 2 articles studied both 3T and 1.5T MRA techniques.39,56 Two 
studies were performed with a 1T scanner.10,51 The rest of the articles evaluated MRA by use 
of 1.5T units. There is a trend toward higher pooled sensitivity and specificity of TOF-MRA 
with 3T units compared with 1.5T scanners, though the 95% confidence intervals overlap 
(Table 7.2). This trend might be caused by the higher resolution of images created with a 
3T MR imaging compared with 1.5T scanners.76 However, the sensitivity and specificity of 
3T CE-MRA is lower than that at 1.5T, though this difference is not statistically significant. 
Again, the small number of studies researching CE-MRA at 3T limits the interpretation 
of results and might be the cause of this nonsignificant difference without reflecting any 
underlying inferiority.39,46,50,56,66 5) A final cause of heterogeneity might be the difference 
in study quality as judged by the GRADE criteria.5,27-35,63 GRADE 4 quality studies tend to 
have higher sensitivity and specificity. This difference reaches significance in sensitivity for 
CE-MRA (Table 7.2). Weighted by GRADE, overall comparisons between TOF-MRA and 
CE-MRA revealed results that were similar to the overall pooled results.
Our results provide a more detailed and updated evaluation of the accuracy of MRA for 
follow-up of coiled intracranial aneurysms than earlier work by Kwee and Kwee.41 Our 
detailed subanalysis of results reveals consistently good performance of MRA techniques 
with pooled sensitivities and specificities well above 80%. For the important question of 
Table 7.2 Subclasses of sensitivity and specificity in TOF-MRA and CE-MRA
TOF-MRA CE-MRA
Sensitivity 
(95% CI)
Specificity 
(95% CI)
Sensitivity 
(95% CI)
Specificity 
(95% CI)
Retrospective
Prospective
90% (85–94%)
85% (81–88%)
87% (82–91%)
86% (82–89%)
93% (85–97%)
82% (77–87%)
95% (90–98%)
82% (75–87%)
2D-DSA
3D-DSA
85% (82–89%)
90% (84–95%)
91% (88–93%)
76% (70–82%)
80% (74–85%)
92% (86–96%)
82% (76–88%)
93% (88–96%)
1.0–1.5T
3T
86% (83–89%)
88% (82–92%)
85% (81–88%)
87% (80–92%)
89% (84–92%)
79% (71–86%)
87% (83–91%)
83% (74–91%)
GRADE 2–3
GRADE 4
87% (82–90%)
86% (81–90%)
86% (81–89%)
87% (83–90%)
77% (70–84%)
92% (86–95%)
85% (79–90%)
90% (85–94%)
Weighted results 86% (85–88%) 86% (85–88%) 87% (85–89%) 88% (86–90%)
Percentages are shown with 95% confidence intervals in parentheses.
DSA = digital subtraction angiography; MRA = magnetic resonance angiography; TOF = time-of-flight; CE = 
contrast-enhanced; GRADE = grades of recommendation, assessment, development, and evaluation; SROC = 
summary receiver operating characteristic.
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residual aneurysms (Raymond grade 4), CE-MRA even provides a pooled sensitivity and 
specificity > 90%, with a lower 95% confidence interval of ≥ 85%. 
concLusIons
This meta-analysis has revealed that MRA has a high diagnostic performance when it comes 
to the detection of residual flow in the follow-up of intracranial aneurysms treated with 
endovascular coil occlusion and therefore should be routinely used for follow-up. CE-MRA 
did not perform significantly better than TOF-MRA, indicating that follow-up with the 
latter should be adequate. 
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Supplemental Table S7.1 Search strategy and results of MEDLINE, Embase, and Cochrane Library 
searches*
Step Search Results
Pubmed Cochrane Embase
1 Subarachnoid Hemorrhage[Mesh] 14,698 811 24,338
2 ((Subarachnoid[tiab] OR Subarachnoidal[tiab]) 
AND (Haemorrhage[tiab] OR Hemorrhage[tiab] 
OR Haemorrhages[tiab] OR Hemorrhages[tiab] OR 
Hematoma[tiab] OR Bleeding[tiab] OR Blood[tiab])) OR 
SAH[tiab] OR SAHs[tiab]
18,856 1,026 22,994
3 #1 OR #2 22,949 1,026 30,916
4 Intracranial Aneurysm[Mesh] 19,390 441 22,471
5 ((Aneurysm[tiab] OR Aneurysms[tiab]) AND (Brain[tiab] OR 
Cerebral[tiab] OR Intracranial[tiab] OR Intra-cranial[tiab] 
OR Basilar Artery[tiab] OR Anterior Communicating 
Artery[tiab] OR Middle Cerebral Artery[tiab] OR Posterior 
Cerebral Artery[tiab] OR Anterior Cerebral Artery[tiab] OR 
Posterior Communicating Artery[tiab]))
18,364 555 22,051
6 #4 OR #5 25,687 555 30,331
7 #3 OR #6 40,494 1,307 50,984
8 Magnetic Resonance Angiography[Mesh] 14,084 487 18,939
9 ((Angiography[tiab] OR Angiographies[tiab]) AND 
(MRI[tiab] OR Magnetic Resonance[tiab] OR MR[tiab])) OR 
((Angiogram[tiab] OR Angiograms[tiab]) AND (MR[tiab] 
OR MRI[tiab])) OR Perfusion Magnetic Resonance 
Imaging[tiab] OR Perfusion Weighted MRI[tiab] OR 
MRA[tiab] OR MRAs[tiab] OR MR angiographic[tiab] OR 
MRI angiographic[tiab]
18,497 681 23,394
10 #8 OR #9 25,439 681 32,287
11 Angiography, Digital Subtraction[Mesh] 6,783 357 11,616
12 ((Angiography[tiab] OR Angiographies[tiab] OR 
Angiographic[tiab]) AND (Digital Subtraction[tiab] 
OR Digital[tiab] OR Catheter[tiab])) OR DSA[tiab] OR 
DSAs[tiab] OR IDSA[tiab] OR Catheter-angiography[tiab]
14,362 632 13,488
13 #11 OR #12 18,002 703 18,709
14 #7 AND #10 AND #13 561 13 744
15 Limits: English 424 12 580
* MeSH = Medical Subject Headings; tiab = title/abstract.
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Supplemental Table S7.3 GRADE analysis
Ref.
Comparison 
with DSA? Limitations Inconsistency Indirectness Imprecision
Pub. 
bias Quality
26 Yes + - - - - 3 / 4
10 Yes - - - - - 4 / 4
37 Yes - - + - - 3 / 4
3 Yes + - - - - 3 / 4
43 Yes + - + - - 2 / 4
51 Yes + - - - - 3 / 4
14 Yes + - - - - 3 / 4
52 Yes + - - - - 3 / 4
79 Yes + - - - - 3 / 4
20 Yes + - - - - 3 / 4
46 Yes - - - - - 4 / 4
74 Yes + - - - - 3 / 4
18 Yes - - - - - 4 / 4
19 Yes + - - - - 3 / 4
23 Yes - - - - - 4 / 4
45 Yes + - - - - 3 / 4
56 Yes + - - - - 3 / 4
70 Yes - - - - - 4 / 4
75 Yes + - - - - 3 / 4
21 Yes - - - - - 4 / 4
38 Yes - - - - - 4 / 4
66 Yes + - - - - 3 / 4
4 Yes - - - - - 4 / 4
39 Yes + - - - - 3 / 4
50 Yes - - - - - 4 / 4
42 Yes - - - - - 4 / 4
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AbstrAct
In the Netherlands, the National Neurosurgical Society has initiated a physician-driven, 
national outcome register for four highly-complex/low-volume disorders: high-grade 
gliomas, pituitary tumors, hydrocephalus in children under the age of two, and aneurysmal 
subarachnoid hemorrhages. The main purpose of the quality register is to ensure that 
each surgeon improves the quality of his/her care. The primary way of achieving this is 
by providing outcome data in a dashboard for each center that is updated two-weekly and 
compared to the center’s historical figures and the national average. Information on the 
number of registered patients per hospital is made public. Initial experiences with registration 
up to 6,000 patients are discussed.
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IntroductIon
Healthcare is at a turning point. Continuously rising costs, despite attempted savings, means 
there is a need to redefine the ultimate goal.8 Reforms aim to achieve the best outcomes 
for the lowest price.2 However, until recently outcomes were not systematically recorded 
and, when they were measured, were hard to compare. Systematic neurosurgical outcome 
registers have emerged in the last few decades, e.g. the Swedish spine registry (Swespine), 
the American College of Surgeons National Surgical Quality Improvement Program (ACS-
NSQIP), and more recently the neurosurgical specific National Neurosurgery Quality and 
Outcome Database (N2QOD), among others.2,3,10,15 Typically, these outcome registries focus 
on spinal procedures, while those for more complex neurosurgical conditions are still being 
developed.10,12 
There is an increasing need to also monitor outcomes for these highly-complex/low-volume 
interventions, because they are often associated with significant morbidity and mortality, 
as well as a high cost per patient. Registers based on hospital coding, typically only provide 
general data, and not the information needed to produce meaningful, casemix-corrected, 
disease-specific outcomes. In the Netherlands, the National Neurosurgical Society has 
initiated a physician-driven, national outcome register for four highly-complex/low-volume 
disorders. This initiative has been embraced and financed by the government organization 
responsible for healthcare inspection and a number of the larger insurance companies. 
After four years of data collection, meaningful information has started to emerge. Patient 
participation in the data-analysis and publication of some of the results will be the next 
phase. This paper describes our experiences with our national outcome register and we 
hope it will provide a framework for other neurosurgical communities. 
neurosurgery In the netherlAnds
The healthcare system in the Netherlands (17 million inhabitants) can be described as a 
well-regulated, socialized medicine. Right from the start of neurosurgery in the country, the 
discipline has been covered by national laws. Government regulations mean that intracranial 
neurosurgery, as well as complex spine and nerve surgery, can only performed in centers with 
appropriate government permission. Complex neurosurgery is thus currently performed 
in 18 hospitals; eight of these are also academic establishments and 10 are major regional 
general hospitals with a recognized top-clinical and training status. Ninety-two percent 
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of the 120 neurosurgeons in the Netherlands are members of the Neurosurgical National 
Society (Nederlandse Vereniging voor Neurochirurgie, NVvN), which is the only such body 
in the country. The maintenance and improvement of the quality of care has always been 
the primary focus of the NVvN, which is why it put in place the national outcome register.
regIstered dIsorders
Four intracranial disorders are subject to registration: high-grade gliomas, pituitary tumors, 
hydrocephalus in children under the age of two, and aneurysmal subarachnoid hemorrhages. 
These specific diseases were chosen because they have a relatively high incidence rate, 
require a complex multidisciplinary treatment, and cause significant mortality and morbidity 
and/or have a lifelong impact. The initial basis of this outcome register was a set of quality 
indicators that were determined by a consensus of the society’s members in 2007 (Table 8.1). 
Table 8.1 Quality indicators per disease classified by structure, process and outcome
Aneurysmal 
subarachnoid 
hemorrhage High grade glioma Pituitary tumors
Hydrocephalus 
under the age of 2
Structure Number of patients Number of patients,
total number of 
tumor related 
craniotomies 
Number of patients Number of patients,
implant registry 
system, protocols for 
secondary treatment 
(physiotherapy)
Process Complications, 
time of bleeding, 
hospitalization, 
and treatment, 
treatment modality
Number of patients 
transferred or 
not accepted for 
treatment
Complications, 
proportion of 
patients operated 
≤ 4 weeks from 
diagnosis (MR), 
proportion of 
patients started 
with radiotherapy ≤ 
8 weeks
Complications, 
time from 
diagnosis to 
treatment
Complications, cause 
of hydrocephalus
Outcome 6 months outcome 
(mRS)
30 days mortality, 
and Survival 
status 6, 12, 18, 
and 24 months 
postoperative, 
Karnovsky 
performance score 
pre, and 6 weeks 
postoperative
30 days mortality,
proportion of cure 
in hormone active 
tumors (Cushing 
& acromegaly), 
proportion of visual 
improvement (if 
applicable)
Percentage of 1 year 
“shunt survival”, 
percentage of shunt 
infections 1 year 
after placement
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orgAnIzAtIon of regIster
The quality register, which has a number of sub-registers, is embedded in the NVvN in the 
form of a special register committee, but is ultimately the responsibility of the organization’s 
board of directors. Each sub-register has its own group of experts, with one delegate per 
center. The main purpose of the quality register is to ensure that each surgeon improves 
the quality of his/her care. The primary way of achieving this is by providing outcome data 
for each center that is updated two-weekly and compared to the center’s historical figures 
and the national average. The data are corrected for case-mix, statistically analyzed, and 
discussed by expert groups. During national meetings of the NVvN, outcome data per center 
are presented, without naming the particular source establishment. Specific items per register 
are also evaluated, and the register is modified where necessary. The results are not surgeon 
based, as complex diseases, that often require treatment in a multidisciplinary setting are 
evaluated. The outcomes are considered to be results arising from the complete chain of 
care. A quality of care control cycle is effectively created in this way for the whole team. It 
is not the NVvN’s intention to criticize any colleague or practice. However, a responsibility 
has been imposed to raise an alert about significant outliers. A system to achieve this in 
a professional manner has been established. Although the system is partly financed by 
healthcare insurance, these companies are not given the data. Quality improvements by 
auto-regulation, which are accomplished by reducing any undesirable variability, with 
subsequent improvements in the mean, are the goal of every stakeholder in the care process. 
Several methods are used to achieve internal data validity: data verification with a random 
sample; data entry by independent data typists; and cross-checks with other registers, e.g. 
a nationwide pathology database. Automated coupling with electronic patient files also 
minimizes drop-outs. The automated coupling transfers primary patient data like date of 
birth and sex, which are encrypted by a trusted third party (ZorgTTP) to guarantee the 
privacy of all patients.   
InItIAl experIences
Initial registration was slow due to a cumbersome registration process and a lack of direct 
feedback about the entered data. This process has now been improved, and up to 6,000 
patients are registered. Information on the number of registered patients per hospital is 
made public at http://www.qrns.nl/stand-van-zaken. Yearly totals per disease are set out in 
Figure 8.1. A benchmark for the total numbers is also provided, if available to estimate the 
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Figure 8.1 Numbers of patients registered in the QRNS system compared to other registers.
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number of missing cases. Possible benchmarks for the total number of patients are: ICD 
coding, calculated incidence, or the database of the Netherlands Cancer Registry (NCR) 
hosted by the Netherlands Comprehensive Cancer Organization (IKNL).1,14 A growing 
number of patients have been registered, although further improvement in this regard is one 
of the most important goals in the near future. The combination of the quality register and a 
scientific interest in nationwide data will provide additional incentives to complete the data 
recording process. Additionally, involving other associated specialists like endocrinologists 
for a pituitary register, neurologists and neurointerventionalists for an aSAH register, and 
neurologists for a glioblastoma register helps in gaining support and motivation for the data 
entry process. Finally, a new interface for the quality register system has been realized by 
automated coupling with electronic patient files as discussed above. 
The new register system produces a two-weekly-updated dashboard. The outcome results 
of each center can thus be visualized and compared to anonymized nationwide data using 
a “statistical mirror”. Deviations from the mean can be detected early by users themselves 
and allows care to be evaluated by, e.g., easy to read funnel plots (Figure 8.2). Detailed 
descriptions per disease will be the subject of forthcoming publications. Although the register 
is used primarily for quality purposes, the scientific publication of nationwide results will 
provide a valuable benchmark for other centers worldwide. Publication of the results will 
be in accordance with each local representative, and the data are submitted to the QRNS 
committee for approval.  
dIscussIon
The QRNS system and organization has two primary goals: registering nationwide (risk-
adjusted) outcomes for complex neurosurgical diseases to provide a benchmark for primary 
outcome measures; and identifying hospital outliers and initiating a quality improvement 
process if required. The success of this quality initiative is achieved by institutional embedding 
nationally with local (hospital) representatives and, by providing real time-feedback. 
Pioneering work on quality measurement has been conducted by Donabedian who outlined 
a conceptual framework for providing insight into healthcare delivery.4,5 This framework 
distinguishes structure, process, and outcome measures. More recently, the topic of quality 
has focused more on value, as raised by Porter.13 Value is defined as health outcomes achieved 
per dollar spent, and is centered on the patient, encompassing the entire cycle of care.13 
Outcomes are condition specific and have multiple hierarchal layers according to this view. 
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Quality evaluation should indeed have outcome measurement as its ultimate goal, although, 
the current healthcare system has barriers when evaluating complex heterogeneous 
conditions using almost all levels of care. Additionally, from a quality improvement point 
of view, it is essential to not only focus on outcomes but also on the process of healthcare 
delivery.11,16 Several approaches to healthcare improvement focus on tools like plan-do-
study-act, six-sigma, lean strategies or combinations of thereof.16 These strategies can be 
applied to different elements of the process of healthcare delivery, and provide tools for rapid 
improvements.9 The QRNS contains outcome as well as structure and process indicators 
for this reason. Moreover, in very complex diseases, natural variabilities in outcomes may 
be high, which could potentially mask a small, but relevant, effect of structure or process 
elements, especially if the number of patients is low. 
Health-related quality of life measures are not yet included, but the glioblastoma dataset 
will be extended in the near future with such questionnaires (QLQ-C30, QLQ-BN20).6,7 
Figure 8.2 Screenshot from online dashboard for aneurysmal subarachnoid hemorrhage: Funnel plot 
for case mix corrected 6 months outcome (percentage of patients with mRS≤2) as a function of total 
number of treated patients per hospital.
The horizontal line indicates nationwide mean percentage of patients with mRS≤2 after 6 months. Dotted 
and interrupted lines of funnel indicate 95% and 99.9% confidence intervals respectively. Anonymized other 
hospitals indicated by blue dots, own hospital depicted in red. Translation of text in figure: Mijn ziekenhuis: 
My hospital, Overige: Other hospitals, Aantal patienten ziekenhuis: Number of patients per hospital, 
Percentage: percentage.
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The costs of care, which are the denominator of the value equation, are not directly evaluated 
by this system.13 Healthcare insurance provides more or less similar payments for each disease 
to different hospitals in the Netherlands. Future benchmarks with other centers in Europe 
or around the world will enable comparisons to be made of the value achieved in healthcare.
The system evaluates aggregated hospital-based rather than individual patient results. How-
ever improvements in overall results eventually lead to in improvements for the individual 
patients. Based on the nationwide results on the outcomes achieved, prediction models 
will be constructed that can identify possible discrepancies at the individual patient level.  
conclusIon
The QRNS is a nationwide quality register system for complex neurosurgical diseases. The 
register is embedded in the Dutch neurosurgical society. An online up-to-date dashboard 
provides insight into the performance of each hospital and can be a starting point for quality 
improvement processes. 
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Quality of care measurement for patients with aneurysmal subarachnoid hemorrhage 
(aSAH) is challenging. The multiplicity of factors that affect the outcome make a transparent 
determination of such a measurement and comparison between measurements difficult. 
This thesis evaluated several aspects of quality of care for patients with aSAH. 
In many complex diseases hospital volume is used as a structure indicator to differentiate 
between hospitals. For aSAH, provider volume is also related to in-hospital mortality in 
reported literature. This finding was discussed in Chapter 2. The meta-analysis of four 
studies representing 36,600 patients revealed a significant relationship that became even 
stronger when one low-quality study was removed. It should be noted that there was no 
uniform cut-off between high and low volume hospitals. To attain comparable results 
between studies, recalculation with dichotomized data centering around 20–30 patients per 
year was performed. This also revealed a significant relationship. It should be noted that the 
data mainly rely on retrospectively coded US hospital databases. Furthermore, treatment 
modality was not evaluated and case-mix correction was not performed, even though both 
are known to be influential for outcome. This meta-analysis does not provide a number 
of patients to be treated by a single neurosurgeon or neurointerventionalist. The results of 
treatment are not the merits of one specialist but the outcome of the chain of care. In the 
scope of quality of care and the increasing demand for centralization, volume number alone 
is not sufficient as a parameter to guide these developments. Hospital volume should be 
seen as one of the cofactors related to outcome. 
Outcomes in aSAH are mainly determined by clinical condition at admission. Comorbidity 
on the other hand also influences outcome. The Charlson Comorbidity Index (CCI), an index 
used to weight several co-morbid conditions, is used for case-mix correction in ischemic 
cerebrovascular disease. In Chapter 3, we evaluated this index for case-mix correction in aSAH. 
We retrospectively analyzed a consecutive series of aSAH patients treated at Radboud university 
medical center (Radboudumc), Nijmegen. A binary logistic regression analysis revealed no 
beneficial use of the CCI in predicting 6-months outcome after aSAH. In this model strong 
predictors of outcome were initial grade (WFNS: World Federation of Neurological Surgeons 
Grading System), age and treatment modality. A larger number of patients could elucidate a 
small but relevant relationship. Hypertension is not included in the CCI but is a frequently 
reported comorbid condition associated with bad outcome. The growing interest in outcome 
registration and associated parameters relevant to outcome places an increasing burden on 
healthcare providers. Focus on items of significant interest is therefore important. The CCI 
as a whole set of comorbidity parameters has no association with outcome. 
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For patients with aSAH, rerupture of the aneurysm prior to treatment is a major cause of 
morbidity and mortality. It is important to recognize risk factors for aneurysmal rebleeding 
and these might help to identify aneurysms that benefit from acute treatment. In Chapter 4 
we investigated whether aneurysm size is related to rebleeding by performing a meta-analysis 
of the published literature. The results of this analysis of 7 studies and 2,121 patients show 
that aneurysm size is an important determinant of aneurysmal rebleeding. It is unlikely 
that age and location are confounding factors. Hypertension was insufficiently registered 
to determine the role of possible confounding effects. Patients with large aneurysms should 
undergo acute treatment rather than ultra-early treatment when feasible. Since the effect size 
of this association might persist for up to 72 hours after the initial bleed, referred patients 
or patients with delayed diagnosis still require urgent treatment. It is important to note that 
there is a potential for publication bias; studies showing no association between aneurysm 
diameter and rebleeding rate are less likely to be published. Also patients who died before 
hospital admission were not included. Confounding factors like time to hospital admission, 
time to aneurysm repair and the effect of aminocaproic acid were insufficiently registered 
to assess their effect on the results. 
Analysis of complications and durability of the treatment of aSAH patients, as part of the 
second and third tiers respectively in the outcome hierarchy, is important. Knowledge of 
these, especially one’s own results, provides a starting point of the improvement cycle. The 
results are presented in Chapter 5 and placed in the context of dual trained neurosurgeons. 
Prospectively collected data from 356 patients treated at the Neurosurgical Centre Nijmegen 
revealed a combined procedural persistent neurological morbidity and mortality after 
endovascular and/or surgical treatment of 2.1% and 1.4% respectively. Overall procedure-
related clinical complication rate was 5.9% and 9.9% respectively. Regarding durability of 
the endovascular treatment recurrence rate was 18.8% and retreatment rate 13.3% (mean 
follow-up of 13.8 months). Open surgical treatment revealed 7.4% neck rests with retreatment 
of 1.9% (mean follow-up of 6.5 months). These results are comparable with those published 
in the literature. Treatment of aSAH by dual trained neurosurgeons is safe and effective.
Healthcare delivery should be centered on the patients and investigate patients’ needs. This 
can be accomplished by an exchange of information between patient and caregiver and 
between patients. An online health community might contribute to this. The value of such 
a community for aSAH patients is reported in Chapter 6. An online, members only, health 
community (mijn SAB, translation: MySAH) was implemented in addition to the usual 
aSAH care at Radboudumc, Nijmegen. The use and usability of the MySAH community were 
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evaluated using a questionnaire. Of the 66 consecutive aSAH patients informed about the 
community, 26 gained access to MySAH and 20 were willing to participate. Participants were 
younger and in a better clinical condition at discharge than non-participants. The patients 
were positive about the contribution to the quality of care but not about the contribution 
to their quality of life. This pilot study indicated a beneficial effect of the online health 
community (MySAH) on the aftercare of aSAH patients, because it provides in easy access 
to relevant information provided by peers or caregivers. The community will mainly be 
useful for patients with a better clinical outcome. 
The possibility of aneurysm recurrence among patients treated endovascularly (coiled) 
necessitates imaging control. Both digital subtraction angiography (DSA) and MR 
angiography (MRA) are suitable, although the latter is a safer and less expensive. Two MRA 
techniques, time of flight (TOF) and contrast enhanced (CE) are the most commonly used 
techniques available. In Chapter 7 the medical literature is systematically reviewed to evaluate 
the accuracy of TOF-MRA and CE-MRA in detecting residual flow in coiled aneurysms. Of 
the 26 studies eligible for inclusion, 24 investigated TOF-MRA, 14 CE-MRA and 12 studies 
assessed both TOF-MRA and CE-MRA. The analysis revealed that MRA (both TOF and CE) 
has a high degree of sensitivity in detecting any recanalization. A subanalysis, however, for 
residual neck or residual aneurysm revealed lower sensitivity and specificity of both MRA 
techniques compared with DSA. This might be explained by the small number of studies 
and the low number of patients these included. False-positive findings seen on DSA that 
might have been caused by pulsation artifacts are another explanation. Since the reference 
standard is DSA, these cases were judged in favor of DSA. This results in false-negative 
values for the MRA and lower sensitivity. Further findings of the subanalysis were lower 
sensitivities of the CE-MRA compared with the TOF-MRA, which were probably related to 
contrast timing in CE-MRA, and longer acquisition time for TOF-MRA. This meta-analysis 
could be subject to several sources of heterogeneity: publication bias, retrospective analysis 
of studies, the use of 2D or 3D (rotational) DSA as a reference, different field strength of 
MR (1, 1.5 or 3T) and finally difference in study quality. 
To improve quality measurement is the first step. Chapter 8 outlines the Dutch neurosurgical 
quality register for aSAH and three other highly-complex/low-volume disorders. The register 
is embedded in the Netherlands Society for Neurosurgery (Nederlandse Vereniging voor 
Neurochirurgie, NVvN). The main goal of the quality register is to provide a benchmark 
for primary outcome measures. Secondly it aims to identify hospital outliers and initiate a 
quality improvement process. This is achieved by providing outcome data for each center in 
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an online dashboard, which is updated once every two weeks and compared to the center’s 
historical figures and national average. The outcome measures are hospital based because it 
evaluates a complex disease requiring treatment in a multidisciplinary setting. The results 
therefore arise from the complete chain of care. A growing proportion of the expected 
number of patients nationwide are registered compared with ICD coding or calculated 
incidence. However, further improvement in registration is needed in the near future. To 
facilitate this an automated coupling with the electronic patient file is being realized. Secondly 
involvement of neurologist and neurointerventionalists in the registration can contribute to 
this. Thirdly combining a quality register with a scientific interest in nationwide data will 
probably provide additional incentives for data entry. 
Future perspectives
The measurement of quality of care in aSAH requires standardized, clear outcome measures. 
Mortality and the modified Rankin scale are used as primary outcome measures in multiple 
clinical trials and the Dutch neurosurgical quality register (QRNS).2-4 Although changes 
in case fatality over the years indicate that these are still relevant outcome measures, more 
refined standardized outcome measures including neuropsychological assessment and 
health-related quality of life should be developed and validated.5,9 This should also include 
a disease- specific, patient-reported, outcome measurement (PROM). Ideally a composite 
score of outcome should be reached that encompasses all relevant items defined in the 
different outcome tiers.6 
Outcomes of care for aSAH are measured on an aggregate level of the hospital. Clearly it is 
considered to be the result of the entire chain of care. From a quality improvement point of 
view, however, these composite results need to be disentangled to identify the differences 
causing the outcomes achieved. Future analysis will elucidate if the registered items are 
distinctive and provide tools for quality improvement. The results should also be applied 
to construct a prediction model. Outcomes can then be evaluated on an individual patient 
level. Discrepancies between attained and predicted outcome warrants evaluation of the 
course of treatment and can highlight possible causes of underperformance. This will be 
an additional stimulus for the improvement of care. 
Although preliminary results of the Dutch neurosurgical quality register (QRNS) are 
promising, the amount of missing values is substantial. Meaningful conclusions cannot 
be drawn at present. High compliance with the quality register is therefore of paramount 
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importance. A highly automated data entry via couplings with the electronic patient file, 
like the UK nephrology register, is the ultimate goal.8 Couplings to import basic patient 
data are a practical first step. A multidisciplinary registration, by all specialists involved 
would probably also decrease the percentage of missing data. After nationwide results 
become reliable, a benchmark with other centers in other countries will place the results in 
a broader perspective. Future clinical trials can use the register as a platform to implement 
an electronic case report form. 
The preliminary results of the quality register (QRNS) in the funnel plot for the treatment of 
aSAH do not indicate any significant difference in hospital performance.1 If these findings 
are confirmed in the near future, once reliable results are available, then it can be questioned 
if the continuation of the register is still justified. Besides the value of such a register from 
a patient counseling perspective and a scientific research perspective, the goal in the future 
should be to improve the mean outcome. Even the slightest improvement in care for this 
disease with major socioeconomic impact justifies the effort and costs associated with the 
register.7 It will be an endeavor to distribute the economic gain to caregivers for the coverage 
of the register for which registration is a non-negligible burden. 
conclusion
In this thesis we have evaluated several aspects of quality of care for patients with aneurysmal 
subarachnoid hemorrhage. There is a relationship between hospital volume and in-hospital 
mortality. However volume number alone is not sufficient as a parameter to assess outcome. 
Systematic outcome measurement is the starting point of quality measurement and a quality 
improvement cycle. Although case-mix correction is important, the Charlson Comorbidity 
Index as a whole has no additional value for this. Patients with large aneurysms should be 
treated acutely, since they have an increased rebleeding risk with high associated morbidity 
and mortality. Analysis of treatment risks and durability of treatment are important secondary 
and tertiary outcome measures. Dual-trained (open and endovascular) neurosurgeons 
have similar results compared to the published literature. Patient involvement by means of 
an online health community in aftercare is beneficial because it provides an easy access to 
relevant information provided by peers or caregivers. It is probably useful for only a subset 
of patients, however. For the follow-up of coiled aneurysms, MRA has a high degree of 
sensitivity compared to DSA in detecting any recanalization and should be used in preference 
to DSA because it has no associated risks. The Dutch neurosurgical quality register (QRNS) 
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provides a visualization of outcome data for aSAH patients, but increased compliance with 
the system is need for reliable results to be achieved. 
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Het is een uitdaging om de kwaliteit van zorg voor patiënten met een aneurysmatische 
subarachnoïdaalbloeding (SAB) te meten. Een hoeveelheid van factoren die invloed hebben 
op de uitkomst maakt het dat het meten en vergelijken hiervan moeilijk is. In dit proefschrift 
zijn verschillende aspecten van de kwaliteit van zorg voor patiënten met een SAB geëvalueerd. 
Voor veel complexe ziektebeelden is aantallen per ziekenhuis een gebruikte structuurindicator 
om tussen ziekenhuizen te differentiëren. Bij patiënten met een SAB is er in de literatuur 
ook een relatie tussen in-ziekenhuis mortaliteit en ziekenhuisvolume. Deze bevinding 
is het onderwerp van hoofdstuk 2. In de meta-analyse van vier studies met in het totaal 
36.600 patiënten werd een statistisch significante relatie aangetoond tussen uitkomst en 
ziekenhuisvolume. Het effect werd zelfs sterker als een studie van lage kwaliteit werd 
verwijderd. Belangrijk is het dat er geen uniforme grens is tussen hoog en laag volume 
ziekenhuizen. Om vergelijkbare groepen te krijgen werd een herberekening verricht met 
gedichotomizeerde data met als grens 20 tot 30 patiënten per jaar per ziekenhuis. Ook dit 
liet een statistisch significante relatie zien. De studies maken wel gebruik van retrospectief 
gecodeerde databases in de Verenigde Staten. Twee elementen die van invloed zijn op 
de uitkomst zijn niet mee genomen: case-mix correctie en behandelingsmodaliteit. 
Deze meta-analyse geeft niet weer hoeveel patiënten door een enkele neurochirurg of 
neurointerventionalist behandeld moeten worden. De resultaten zijn niet de verdienste 
van slechts één specialist, echter van de gehele zorgketen. In het licht van kwaliteit van zorg 
en de toenemende vraag om centralisatie zijn ziekenhuisaantallen alleen onvoldoende om 
hier richting aan te geven. Ziekenhuisvolume moet als een van de cofactoren gezien worden 
gerelateerd aan uitkomst. 
De belangrijkste factor die de uitkomst bepaalt bij patiënten met een SAB is de klinische 
conditie bij presentatie in het ziekenhuis. Daarnaast kan comorbiditeit ook de uitkomst 
beïnvloeden. De Charlson Comorbidity Index (CCI) is een index om verschillende 
comorbiditeiten te wegen, en kan gebruikt worden in ischemische beroerte. In hoofdstuk 3 
evalueren we de waarde van de CCI voor patiënten met een SAB. Alle opeenvolgende SAB-
patiënten behandeld in het Radboudumc zijn retrospectief geanalyseerd. Analyse liet geen 
toegevoegde waarde zien van de CCI in het voorspellen van de uitkomst na 6 maanden. In 
de analyse kwamen initiële klinische conditie (WFNS: World Federation of Neurological 
Surgeons Grading System), leeftijd en behandelingsmodaliteit als sterke voorspellers voor 
de uitkomst naar voren. Mogelijk is het aantal patiënten te klein om een onderliggende 
significante relatie aan te tonen. Daarnaast is hypertensie gerelateerd aan een slechte 
uitkomst en die niet in de CCI opgenomen is. De toenemende interesse in uitkomstregistratie 
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en daarmee gepaard gaande registratie van parameters relevant voor de uitkomst wordt 
veelal als een last ervaren door zorgverleners. Het is derhalve noodzakelijk om parameters 
te registreren die van belang zijn voor een gewogen uitkomstmeting. De CCI heeft geen 
toegevoegde waarde voor het wegen van comorbiditeit in de uitkomst bij SAB-patiënten. 
Het krijgen van een hernieuwde bloeding voor aanvang van de behandeling is een belangrijke 
oorzaak van morbiditeit en overlijden bij patiënten met een SAB. Daarom is het van belang 
om risicofactoren voor hernieuwde bloeding te herkennen en om patiënten te selecteren die 
baat hebben bij acute behandeling. In hoofdstuk 4 wordt de relatie tussen aneurysmagrootte 
en de kans op hernieuwde bloeding voor behandeling onderzocht door middel van een 
meta-analyse van de literatuur. Het resultaat van deze analyse van 7 studies met in het totaal 
2.121 patiënten laat zien dat aneurysmagrootte een belangrijke factor is gerelateerd aan 
hernieuwde bloeding. Het is onwaarschijnlijk dat de resultaten beïnvloed worden door de 
leeftijd van de patiënt en de plaats van het aneurysma. Over hypertensie kan geen uitspraak 
gedaan worden omdat hiervoor de gegevens onvoldoende waren. Patiënten met een groot 
intracranieel aneurysma moeten indien mogelijk eerder een acute dan een vroege (binnen 
24 uur) behandeling ondergaan. Omdat de relatie tussen grootte en risico op hernieuwde 
bloeding de eerste 72 uur aan lijkt te houden na de eerste bloeding, geldt de noodzaak tot 
acute behandeling ook voor patiënten die verwezen zijn vanuit andere centra of patiënten 
waarbij de diagnose vertraagd gesteld is. Deze studie kan beïnvloed zijn door publicatiebias 
omdat studies die geen relatie zouden laten zien mogelijk minder makkelijk gepubliceerd 
worden. Tevens is het zo dat patiënten die overleden zijn voor ziekenhuisopname niet in deze 
studies zijn opgenomen. Andere zogenaamde confounders zoals tijd tot ziekenhuisopname, 
tijd tot operatie en het effect van aminocapronzuur, zijn onvoldoende gedocumenteerd om 
de invloed op de uitkomst te beoordelen. 
Analyse van complicaties en duurzaamheid van de behandeling, als onderdeel van de 
tweede en de derde rij in de uitkomsthiërarchie, is belangrijk. De analyse van resultaten 
van de behandeling bieden een startpunt voor de verbeteringscyclus. De eigen resultaten 
zijn onderwerp van hoofdstuk 5 en worden bediscussieerd met specifieke aandacht voor 
open en endovasculair werkende (“hybride”) neurochirurgen. Hiertoe zijn de prospectief 
geregistreerde gegevens van 356 SAB-patiënten, behandeld op de afdeling neurochirurgie 
van het Radboudumc te Nijmegen, geanalyseerd. Er is een gecombineerde blijvende 
morbiditeit en mortaliteit van endovasculaire of open chirurgische behandeling van 2,1%, 
respectievelijk 1,4%. Het procedurele complicatierisico was 5,9%, respectievelijk 9,9%. Wat 
betreft de duurzaamheid werd er een nekrest van het aneurysma gezien bij endovasculaire 
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behandeling in 18,8% en was er noodzaak tot herbehandeling in 13,3% (gemiddelde follow-
up van 13,8 maanden). Bij de open chirurgische behandeling waren er nekresten in 7,4% met 
herbehandeling in 1,9% (gemiddelde follow-up van 6,5 maanden). De resultaten zijn hiermee 
in lijn met de gepubliceerde. De behandeling van SAB-patiënten door neurochirurgen die 
zowel endovasculaire als open chirurgische behandeling bieden is veilig en effectief. 
Zorg moet gecentreerd zijn rondom de patiënt. De behoeften van de patiënt moeten continu 
geëvalueerd worden. Dit kan bereikt worden door het uitwisselen van informatie tussen 
patiënt en zorgverlener en tussen patiënten onderling. Een online health community kan 
hieraan bijdragen. De waarde van een dergelijke community voor SAB-patiënten wordt 
besproken in hoofdstuk 6. Een online health community, genoemd Mijn SAB, voor SAB-
patiënten is geïmplementeerd in aanvulling op de gebruikelijke SAB-zorg in het Radboudumc, 
Nijmegen. Het gebruik en de bruikbaarheid van deze community werden geëvalueerd met 
behulp van een enquête. Zesenzestig opeenvolgende SAB-patiënten werden geïnformeerd 
over de community, waarvan er 26 toegang verkregen tot Mijn SAB en 20 participeerden in 
het onderzoek. De patiënten beoordeelden de bijdrage van de community aan de kwaliteit van 
zorg als positief, maar niet aan de kwaliteit van leven. Deze pilotstudie liet de aanvullende 
waarde van de online health community (Mijn SAB) zien op de nazorg voor SAB-patiënten. 
Mijn SAB voorzag in laagdrempelige toegang tot belangrijke informatie van medepatiënten 
of zorgverleners. Vooral patiënten in een betere klinische conditie hebben hier voordeel bij. 
Voor endovasculair behandelde (gecoilde) aneurysmata is controle nodig gezien de kans 
op rekanalisatie van het aneurysma. Zowel digitale subtractie angiografie (DSA) als 
magnetische resonantie angiografie (MRA) kunnen hiervoor gebruikt worden, hoewel de 
laatst genoemde veiliger en minder duur is. Twee MRA-technieken, te weten time of flight 
(TOF) en met contrast (contrast enhanced: CE), zijn de meest beschikbare technieken. In 
hoofdstuk 7 is de medische literatuur systematisch geëvalueerd om de nauwkeurigheid 
van TOF-MRA en CE-MRA in het detecteren van aneurysmarekanalisatie te bepalen. Van 
de 26 studies die voldeden aan de inclusiecriteria, evalueerden er 24 TOF-MRA, 14 CE-
MRA en 12 zowel TOF- als CE-MRA. De analyse liet zien dat MRA (TOF en CE) een hoge 
sensitiviteit heeft in het detecteren van elke vorm van rekanalisatie. Een subanalyse naar of 
nekrest, of restaneurysma, liet echter zien dat beide MRA-technieken een lagere sensitiviteit 
en specificiteit hebben dan DSA. Een verklaring hiervoor is mogelijk het geringe aantal 
studies en het lage aantal patiënten dat hierin geïncludeerd is. Een andere verklaring is 
dat fout-positieve bevindingen op de DSA het gevolg zijn van pulsatie-artefacten. Omdat 
DSA de gouden standaard is, worden deze gerekend in het voordeel van DSA. Dit leidt tot 
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fout-negatieve waarden voor de MRA met een lagere sensitiviteit. Andere bevindingen van 
de subanalyse waren de lagere sensitiviteit van CE-MRA vergeleken met TOF-MRA, wat 
waarschijnlijk gerelateerd is aan de contrasttiming in CE-MRA, en de langere acquisitietijd 
voor TOF-MRA. In deze meta-analyse kan er heterogeniteit tussen de geïncludeerde studies 
bestaan. Dit kan komen door publicatiebias, retrospectieve analyses van studies, het wisselend 
gebruik van 2D of 3D (rotatie) DSA als referentie, verschillende veldsterkten voor de MRI 
(1, 1,5 of 3T) en ten slotte verschil in kwaliteit van de studies. 
Kwaliteitsverbetering begint met het meten van de huidige stand van zaken. In hoofdstuk 8 
wordt het Nederlands kwaliteitsregistratiesysteem (QRNS: Quality Registry NeuroSurgery) 
voor SAB-patiënten en drie andere hoog complex / laag volume ziektebeelden beschreven. 
Het registratiesysteem is ingebed in de Nederlandse Vereniging voor Neurochirurgie (NVvN) 
met als belangrijkste doel een ijkpunt te geven voor primaire uitkomsten bij de ziektebeelden. 
Daarnaast heeft het tot doel om uitschieters te signaleren en een verbeteringsproces in 
te kunnen zetten. Het direct inzichtelijk maken van de uitkomstgegevens in een online 
dashboard, dat elke 2 weken geactualiseerd wordt, draagt hiertoe bij. De uitkomst van 
het eigen ziekenhuis wordt afgezet tegen het landelijk gemiddelde. Er is gekozen voor 
uitkomstmaten op ziekenhuisniveau omdat er complexe ziektebeelden geëvalueerd worden 
die multidisciplinaire zorg vragen. De resultaten van behandeling zijn dus het product 
van de gehele zorgketen. Er is een groeiend percentage patiënten dat geregistreerd wordt, 
uitgaande van totalen door ICD-coderingen of een berekende incidentie. De registratie zal 
moeten verbeteren in de nabije toekomst. Hiervoor wordt een automatische koppeling met 
het elektronische patiëntendossier gerealiseerd. Tevens kan de betrokkenheid van neurologen 
en neurointerventionalisten bij de registratie tot een verbetering leiden. Ten slotte kan het 
combineren van het kwaliteitsregistratiesysteem met wetenschappelijke interesse in landelijke 
uitkomstgegevens leiden tot een verbetering in de invoer van data. 
ToekomsTblik
Om kwaliteit van zorg voor SAB-patiënten te meten is het van belang gestandaardiseerde 
heldere uitkomstmaten te hebben. Mortaliteit en de modified Rankin scale zijn primaire 
uitkomstmaten die in veel trials en het Nederlands kwaliteitsregistratiesysteem (QNRS) 
gebruikt worden.2-4 Hoewel het zo is dat veranderingen in deze uitkomstmaten over de jaren 
aangeeft dat dit enkele nog steeds relevante parameters zijn, is er ook een noodzaak tot meer 
verfijnde uitkomstmaten, zoals neuropsychologische testen en gezondheidsgerelateerde 
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kwaliteit van leven uitkomsten, welke ontwikkeld en gevalideerd moeten worden.5,9 Dit zou 
ook een ziektespecifieke patiëntgerapporteerde uitkomstmaat (een zogenaamde PROM) 
moeten bevatten. Idealiter zou een samengestelde score gemaakt moeten worden die alle 
relevante uitkomsten van de verschillende uitkomstlagen bevat.6 
De uitkomsten van zorg voor patiënten met een SAB worden gemeten op het niveau 
van het ziekenhuis. Dit is een logische keuze aangezien de uitkomst het resultaat is van 
het functioneren van de gehele zorgketen. Vanuit het oogpunt van kwaliteitsverbetering 
is het nodig deze samengestelde uitkomst te ontwarren om oorzaken van verschillen te 
kunnen identificeren. Toekomstige analyses zullen laten zien of de geregistreerde items 
onderscheidend zijn en een handvat bieden voor kwaliteitsverbetering. De resultaten kunnen 
ook gebruikt gaan worden voor het maken van een predictiemodel. Dan is het mogelijk 
om op individueel patiëntniveau uitkomsten te voorspellen. Discrepanties in bereikte en 
voorspelde uitkomst nopen tot evaluatie van de behandeling en kunnen eventuele problemen 
aan het licht brengen. Dit zal een toegevoegde stimulus zijn voor de verbetering van zorg. 
Hoewel de eerste resultaten van het Nederlands kwaliteitsregistratiesysteem (QRNS) 
veel belovend zijn, is het aantal missende items nog aanzienlijk. Tot op heden kunnen 
betekenisvolle conclusies nog niet getrokken worden. Het volledig invullen van het 
kwaliteitsregistratiesysteem is daarom van kardinaal belang. Het uiteindelijke doel is een 
volledig automatische gegevensinvoer met behulp van koppelingen met het elektronisch 
patiëntendossier zoals het geval is bij het nefrologieregister in het Verenigd Koninkrijk.8 
Koppelingen om basale patiëntgegevens over te brengen is een eerste praktische stap. Ook 
kan een multidisciplinaire registratie door alle betrokken specialisten bijdragen aan een 
afname van missende gegevens. Nadat landelijke data betrouwbaar zijn, kan een vergelijk met 
andere centra in andere landen de resultaten in een breder perspectief zetten. Toekomstige 
klinische trials kunnen het registratiesysteem als een platform gebruiken om daar het 
casusformulier onder te brengen. 
De eerste resultaten van het kwaliteitsregistratiesysteem (QRNS) laten in de funnelplot voor de 
behandeling van SAB-patiënten geen significante verschillen zien in ziekenhuisuitkomsten.1 
Indien deze bevindingen in de nabije toekomst bevestigd worden, als betrouwbare 
resultaten beschikbaar worden, dan kan men zich afvragen of het continueren van een 
dergelijk registratiesysteem nog gerechtvaardigd is. Naast de waarde van een dergelijk 
registratiesysteem om patiënten te kunnen voorlichten en intrinsieke wetenschappelijke 
waarde, moet het uiteindelijke doel zijn de gemiddelde uitkomst te verbeteren. Zelfs de 
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geringste verbetering in zorg voor deze ziekte met grote socio-economische gevolgen 
rechtvaardigt de inspanningen en kosten gepaard gaande met deze kwaliteitsregistratie.7 
Het zal een uitdaging worden om de economische winst die behaald gaat worden ook te 
verdelen onder zorgverleners voor de dekking van het registratiesysteem, wat een niet 
onaanzienlijke inspanning vergt. 
ConClusie
In dit proefschrift zijn er verschillende aspecten van de kwaliteit van zorg voor patiënten 
met een aneurysmatische subarachnoïdaalbloeding geëvalueerd. Er is een relatie tussen 
ziekenhuisaantallen en ziekenhuissterfte. Echter het afmeten van de uitkomst aan de aantallen 
is onvoldoende. Het systematisch meten van de uitkomst is het startpunt van kwaliteitsmeting 
en de kwaliteitsverbeteringcyclus. Hoewel case-mix correctie belangrijk is, heeft de Charlson 
Comorbidity Index daarvoor geen toegevoegde waarde. Patiënten met grote aneurysmata’s 
dienen acuut behandeld te worden omdat hierbij een verhoogd hernieuwd bloedinggevaar is 
met vaak hoge morbiditeit en mortaliteit. Analyse van behandelingsrisico’s en duurzaamheid 
van behandeling zijn relevante secundaire en tertiaire uitkomstmaten. Neurochirurgen die 
zowel open als endovasculaire behandeling uitvoeren hebben vergelijkbare resultaten met 
gepubliceerde series. De betrokkenheid van de patiënt in de nazorg door middel van een 
online health community wordt als een winst beschouwd, omdat het laagdrempelig toegang 
geeft tot informatie van medepatiënten of zorgverleners. Wel is het zo dat het waarschijnlijk 
waardevol is voor een deel van de patiënten. Voor de controle van gecoilde aneurysmata 
heeft MRA een hoge sensitiviteit in vergelijk met DSA in het detecteren van rekanalisatie, 
en moet daarom bij voorkeur gebruikt worden omdat het geen risico’s heeft zoals die aan 
een DSA verbonden zijn. Het Nederlands neurochirurgisch kwaliteitsregistratiesysteem 
(QRNS) voorziet in het inzichtelijk maken van de uitkomsten van SAB-patiënten, echter 
volledige informatie is noodzakelijk om betrouwbare gegevens te verkrijgen. 
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